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ABSTRACT 
 
Background 
Oxidative stress has been implicated in the development of a number of conditions including 
amongst others cancer, arthritic disorders and cardiovascular disease. Pycnogenol is a 
herbal dietary supplement derived from French maritime pine bark extract. Pycnogenol is 
standardised to contain 70 ± 5% procyanidin which is a powerful antioxidant. Pycnogenol is 
marketed as a supplement for preventing or treating a wide range of chronic conditions. 
Although several randomised controlled trials of Pycnogenol have been conducted to date, 
this evidence has not yet been systematically reviewed. 
 
Objectives 
The aim was to carry out a systematic review in order to assess the efficacy and safety of 
Pycnogenol for the treatment of chronic disorders. 
 
Search methods 
The electronic databases CENTRAL (until 18 September 2010), MEDLINE (until 18 
September 2010) and EMBASE (until 13 October 2010) were searched, as well as three trial 
registries. Furthermore the manufacturer of Pycnogenol was contacted and bibliographies of 
included studies were hand-searched. 
 
Selection criteria 
Randomised controlled trials (RCTs) evaluating the effectiveness of Pycnogenol in adults or 
children with any chronic disorder were included. The primary outcomes were any clinical 
outcomes directly related to the disorder (stratified as participant- and investigator-reported) 
as well as all-cause mortality. Adverse events and biomarkers of oxidative stress were also 
assessed. 
 
Data collection and analysis 
Two authors independently assessed trial eligibility, extracted all data and judged 
methodological quality. A third author additionally extracted information on outcomes and 
results. With two exceptions, results for outcomes across studies could not be pooled mainly 
due to poor quality reporting. Study authors were contacted for additional information. 
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Results 
This review includes 15 RCTs with a total of 791 participants that have evaluated 
Pycnogenol for the treatment of seven different chronic disorders. The disorders included 
asthma (2 studies; N = 86), attention deficit hyperactivity disorder (1 study; N = 61), chronic 
venous insufficiency (2 studies; N = 60), diabetes mellitus (4 studies; N = 201), erectile 
dysfunction (1 study; N = 21), hypertension (2 studies; N = 69) and osteoarthritis of the knee 
(3 studies; N = 293). Two of the studies were conducted exclusively in children; the others 
involved adults. Due to small sample size, limited numbers of trials per condition, variation in 
selected outcomes and outcomes measures and the risk of bias no definitive conclusions 
regarding the efficacy or safety of Pycnogenol are possible. 
 
Authors’ conclusions 
Current evidence is insufficient to support Pycnogenol use for the treatment of any chronic 
disorder. Well designed, adequately powered trials are recommended to establish the value 
of this treatment.   
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OPSOMMING 
 
Inleiding 
Oksidatiewe stres blyk ’n rol te speel in die ontwikkeling van ’n verskeidenheid siektes onder 
andere kanker, artritis en kardiovaskulêre siektes.  Pycnogenol, ‘n kruie-bevattende 
dieetaanvulling wat uit Franse denneboombas vervaardig word, is gestandaardiseer om 70 ± 
5% prosianidien – ’n kragtige anti-oksidant – te bevat.  Die produk word bemark om ‘n wye 
reeks chroniese siektes te voorkom of te behandel.  Alhoewel daar tot op hede verskeie 
kliniese proewe op Pycnogenol uitgevoer is, is die uitkomstes nog nie met behulp van ‘n 
stelselmatiese oorsig geëvalueer nie.   
 
Doelwitte 
Die doel van hierdie studie was om met behulp van ‘n stelselmatiese oorsig die 
doeltreffendheid en veiligheid van Pycnogenol ten opsigte van die behandeling van 
chroniese siektes te evalueer. 
 
Soektogstrategie 
Die elektroniese databasisse CENTRAL (tot 18 September 2010), MEDLINE (tot 18 
September 2010) en EMBASE (tot 13 Oktober 2010) is deursoek, asook drie registers met 
kliniese proewe.  Verder is die vervaardiger van Pycnogenol gekontak en is daar met die 
hand deur bibliografieë van ingeslote studies gesif. 
 
Keuringskriteria 
Ewekansige gekontroleerde proewe (RCT’s) is ingesluit waarin die effektiwiteit van 
Pycnogenol in volwassenes of kinders met enige chroniese siekte geëvalueer is.  Enige 
kliniese uitkomste wat direk aan die chroniese siekte verwant is (gesorteer as deelnemer- of 
ondersoeker-gerapporteerde uitkomstes) asook mortaliteit (enige oorsake) is as die primêre 
uitkomstes ondersoek.   
 
Dataversameling en -ontleding 
Twee navorsers het onafhanklik van mekaar proewe gekeur, alle relevante data onttrek en 
gehalte van die metodiek beoordeel.  ‘n Derde navorser het die resultate van die uitkomstes 
bykomend onttrek.  Met twee uitsonderings, kon resultate van uitkomstes van die 
verskillende ingeslote studies kon nie statisties saamgevoeg word nie, hoofsaaklik as gevolg 
van swak rapportering.  Skrywers van die ingeslote studies is in verband met die verlangde 
inligting gekontak. 
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Resultate 
Vyftien RCT’s met ‘n totaal van 791 deelnemers is ingesluit.  In hierdie studies is Pycnogenol 
vir die behandeling van sewe verskillende chroniese siektes geëvalueer: asma (2 studies; N 
= 86), aandagafleibaarheid-hiperaktiwiteitsgebreksindroom (1 studie; N = 61), chroniese 
veneuse ontoereikendheid (2 studies; N = 60), diabetes mellitus (4 studies; N = 201), 
erektiele disfunksie (1 studie; N = 21), hipertensie (2 studies; N = 69) en osteo-artritis van 
die knie (3 studies; N = 293).  Twee van hierdie studies is uitsluitlik met kinders gedoen; die 
res was volwassenes.  As gevolg van klein steekproewe, ‘n beperkte aantal studies per 
siekte, wisseling in uitkomstes en die risiko vir sydigheid kan geen definitiewe gevolgtrekking 
oor die doeltreffendheid en veiligheid van Pycnogenol gemaak word nie. 
 
Skrywers se gevolgtrekking 
Tans is daar nie voldoende wetenskaplike bewyse om Pycnogenol-gebruik vir die 
behandeling van enige chroniese siekte aan te beveel nie.  Goed ontwerpte proewe met ‘n 
voldoende aantal deelnemers word aanbeveel om die waarde van hierdie behandeling 
onomwonde vas te stel.   
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LIST OF DEFINITIONS 
 
Free radicals 
Atoms, molecules or ions which contain one or more unpaired electrons and are capable of 
independent existence.(Cos 2004) 
 
Oxidative stress 
Refers to a state of imbalance between the production of reactive oxygen species and the 
body’s ability to defend itself against the deleterious effect of oxidation.(Sies 2005; Whitney 2002) 
 
Proanthocyanidin 
A powerful antioxidant found in a variety of foods, especially fruit such as grapes, berries, 
pomegranates, apples and pears.(Beecher 2003) 
 
Procyanidin 
A subtype of proanthocyanidin, a member of the flavonoid subgroup of polyphenols.(Scalbert 
2000)
 
 
Pycnogenol 
A herbal dietary supplement derived from French maritime pine bark extract which is 
standardised to contain 70 ± 5% procyanidin.(Oliff 2010; Schonlau 2010) 
 
Reactive oxygen species 
A collective term for free radicals (e.g. superoxide anion, hydroxyl, nitric oxide) and certain 
non-radicals (e.g. hydrogen peroxide, hypochlorous acid, ozone) which are both by-products 
of oxygen metabolism in the body.(Cos 2004)  
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INTRODUCTION 
 
Every health professional around the world had taken the Hippocratic Oath, promising to 
treat ill health to the best of his/her ability.  In practice this translates to integrating the 
following three aspects before a clinical decision can be made:  the knowledge, expertise 
and skills of the professional; the patient’s values and preferences; and the best available 
evidence.(1)  This task of keeping up to date is not easy as there is vast amount of 
biomedical literature electronically available.(2)  However, this task has been made much 
simpler by applying clinical epidemiology, the science, explicitly in the form of evidence-
based health care.(3)  This field of epidemiology arose in the late 1960s due to the growing 
awareness that laboratory experiments and experience alone are not sufficient for making 
clinical decisions.(2, 4)  Clinical epidemiology and evidence-based health care are umbrella 
concepts which include all health care fields, including nutrition.  The main objective of 
nutritional epidemiology is thus to provide the best possible scientific evidence to support an 
understanding of the role of nutrition in the causes and prevention of ill health.(5) 
 
The practice of evidence-based nutrition involves five essential steps:  identifying knowledge 
gaps and converting it into answerable questions; finding the best evidence to answer the 
question; appraising the evidence critically; and applying the evidence and evaluating 
performance.(3)  The latter involves patient follow-up as well as synthesizing research which 
build on the principle that science is cumulative.(6)  Research synthesis is defined by the 
World Health Organization as the process through which two or more research studies are 
assessed with the objective of summarizing the evidence relating to a particular question.(6)  
Overviews, (traditional) reviews, systematic reviews and meta-analysis are types of research 
synthesis.  The validity of these types of research synthesis is dependent on the 
methodological quality involved.(7)  Overviews and traditional reviews are rarely explicit about 
how primary studies were selected, assessed and analysed.(7)  This directly influences the 
quality of the findings since readers are not able to assess potential bias in the review 
process.(7)  A systematic review on the other hand, reduces bias by the systematic 
identification, appraisal, synthesis and, if relevant, statistical aggregation of all relevant 
studies (meta-analyses) on a specific topic according to a pre-determined and explicit 
method.(8)  The findings of a systematic review depend on the studies that are to be included 
and since randomised controlled trials are the golden standard of primary research, a 
systematic review of randomised controlled trials (which may or may not include meta-
analyses) is the highest level of evidence, especially when it comes to health care 
interventions.(9)   
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In general, systematic reviews are not controlled but resources such as workshops and 
courses, textbooks, the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) checklist and Assessment of Multiple Systematic Reviews (AMSTAR) 
tool are available to ensure transparent and reproducible methodology of high quality.  An 
international non-profit organization that eases this process in various ways is the Cochrane 
Collaboration which was founded in 1993 in Oxford, England. Its primary aim is to help 
people make well-informed decisions about health care by preparing, maintaining and 
promoting the accessibility of systematic reviews of the evidence that underpins these 
reviews.(10)  Cochrane reviews are supported by more than 50 different Cochrane Review 
Groups which core functions are, amongst others, to focus on a particular health care area, 
avoid duplication of reviews as well as maximising the quality of reviews by assisting in the 
correctness of the content, putting together search strategies, statistical support and 
thorough peer reviewing.  A unique feature of Cochrane reviews in the Cochrane Database 
of Systematic Reviews is the fact that regular updates with the latest evidence are required.  
Updating involves conducting searches for new studies on a regular basis (frequency 
depends on the specific health care area), followed by all the other systematic steps when 
relevant studies are found.   
 
Antioxidants in general, and the flavonoid proanthocyanidin in particular, is a very broad and 
interesting field of research.  In the electronic database PubMed alone there are 1131 results 
(17 January 2011) when searching for titles and/or abstracts containing the terms 
‘proanthocyanidin OR procyanidin’.  These studies include laboratory, animal and human 
studies that focus on a wide variety of characteristics, from the bioavailability of 
proanthocyanidin to the clinical effect that this substance may have on various medical 
conditions.  This project’s focus is on the latter area of research.   
 
Pycnogenol is a proanthocyanidin-containing supplement that is marketed for its antioxidant 
properties.  There are many such supplements available globally, but Pycnogenol is the best 
researched one.  According to the website of the manufacturer, Horphag Research Ltd, 
there are more than 230 scientific articles and clinical trials that have confirmed over the past 
forty years Pycnogenol’s safety, absence of toxicity and clinical efficacy.(11)  People around 
the world pay a lot of money for supplements such as Pycnogenol which is marketed to aid 
in the treatment of an array of conditions including  attention deficit hyperactivity disorder, 
asthma, cholesterol/dyslipidaemia, chronic venous insufficiency, diabetes, dysmenorrhoea, 
endometriosis, erectile dysfunction, hypertension, melasma, muscle cramps, osteoarthritis, 
peri-menopause, platelet function and retinopathy.(12)  This is a comprehensive claim and as 
a result it was decided to evaluate the evidence systematically to establish whether these 
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claims related to Pycnogenol are justified or not.  Against this background this Cochrane 
review was therefore undertaken to assess the efficacy and safety of Pycnogenol for the 
treatment of chronic disorders. 
 
Another interesting area to explore is, for example, the difference between the clinical 
efficacy of proanthocyanidin in whole food such as fruit and vegetables versus supplements 
or extracts in the prevention and/or treatment of medical disorders.  Although the 
proanthocyanidin dosage in the supplements will probably be higher than one can get by 
eating decent portions of fruit and vegetables daily, the interaction between nutrient and 
non-nutritive components in fruit and vegetables may be responsible for superior health 
benefits.(13)  However, this would be a project on its own and is beyond the scope of this 
project. 
 
 
References to the Introduction and Closing Remarks are presented on the last page of this 
project.
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Plain language summary 
 
Use of the antioxidant supplement Pycnogenol to treat a variety of chronic 
disorders 
 
Pycnogenol is a supplement containing approximately 70% procyanidin which is extracted 
from French pine bark. Procyanidin is a powerful antioxidant which also occurs widely in 
food such as grapes, berries, pomegranates, red wine and various nuts. There are many 
procyanidin-containing supplements worldwide which is marketed to neutralise reactive 
oxygen species (ROS; generally referred to as free radicals in the media). Everyone is 
bombarded daily by ROS for example through exercise, stress, smoking, air pollution and 
exposure to ultraviolet light. ROS can cause harm in various ways, but on the other hand it 
also have several beneficial functions in humans. It is thus possible that excessive amounts 
of antioxidants may have a negative effect and that a balance between ROS and 
antioxidants may be critical for maintaining health. The objectives of this systematic review 
were then to assess the efficacy and safety of Pycnogenol as treatment for any chronic 
disorder. We included 15 randomised controlled trials which addressed seven different 
chronic conditions: asthma (2 studies), attention deficit hyperactivity disorder (ADHD) (1 
study), chronic venous insufficiency (2 studies), diabetes (4 studies), erectile dysfunction (1 
study), hypertension (2 studies) and osteoarthritis (3 studies). Due to small sample size and 
limited numbers of trials per condition no definite conclusions regarding the efficacy and 
safety of Pycnogenol are possible. 
 
Background 
 
Description of the condition  
Reactive oxygen species (ROS) is a collective term for free radicals (e.g. superoxide anion, 
hydroxyl, nitric oxide) and certain non-radicals (e.g. hydrogen peroxide, hypochlorous acid, 
ozone) which are both by-products of oxygen metabolism in the body (Cos 2004). Free 
radicals are atoms, molecules or ions which contain one or more unpaired electrons and are 
capable of independent existence (Cos 2004). Sources of ROS include radiation, exercise, 
stress, smoking, air pollution, ultraviolet light and some foods (Whitney 2002). While ROS 
performs important functions within cells, most notably the destruction of pathogens 
phagocytosed by white cells, they may cause significant damage in large amounts. Oxidative 
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stress refers to a state of imbalance between the production of ROS and the body's ability to 
defend itself against the deleterious effect of oxidation (Sies 2005; Whitney 2002). Damage 
to cellular structures may ensue, leading to the development of disease (Ammar 2009; Cos 
2004; Watson 2006; Whitney 2002). 
 
Oxidative stress has been implicated in the development of a number of conditions including 
cardiovascular disease, arthritic and rheumatic disorders, cancer, inflammatory bowel 
disease, Alzheimer's disease, Parkinson's disease and cataracts (Litchford 2008). While the 
exact role of ROS in the pathogenesis of these diseases remains unclear, the following are 
some mechanisms that are thought to be important:  
• Oxidative damage to cellular DNA may lead to the development of certain 
malignancies (Nijveldt 2001; Whitney 2002);  
• Oxidation of low density lipoproteins (LDL) may accelerate plaque formation in 
arteries, increasing the likelihood of developing cardiovascular diseases (Nijveldt 
2001; Whitney 2002);  
• Oxidation of poly-unsaturated fatty acids in cell membranes may hinder blood flow 
and contribute to cardiovascular problems (Whitney 2002); 
• Oxidative stress encourages telomere (the non-gene terminal end of a chromosome 
which protects the chromosome from destruction) instability and dysfunction in 
chondrocytes (cartilage cells), which may result in cartilage ageing and the 
development of osteoarthritis (Yudoh 2005); 
• Dopamine-derived ROS and oxidized dopamine metabolites are toxic to neurons of 
the substantia nigra (part of the brain stem that release neurotransmitters, such as 
dopamine, that is important for the control of movement and coordination) which may 
lead to Parkinson's disease (Hald 2005).  
 
Description of the intervention  
Pycnogenol is a herbal dietary supplement derived from French maritime pine bark extract. 
The trees (Pinus pinaster Ait. subsp. altantica) are exclusively grown in Landes de 
Gascogne, Southwest France (Oliff 2010). Fresh pine bark is powdered and extracted with 
water and ethanol in a process patented by the manufacturer Horphag Research, Geneva, 
Switzerland (Oliff 2010). Pycnogenol is standardised to contain 70 ± 5% procyanidin 
(condensed oligomeric catechin and epicatechin) (Oliff 2010; Schonlau 2010). 
 
Procyanidin is a subtype of proanthocyanidin, a member of the flavonoid subgroup of 
polyphenols (Scalbert 2000). It is a powerful antioxidant found in a variety of fruits such as 
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grapes, berries, pomegranates, apples and pears, as well as in various nuts, pine bark, red 
wine, tea and chocolate (Beecher 2003; Cos 2004). Proanthocyanidin containing 
supplements are sold under a variety of brand names worldwide such as Bioxidin©, 
ActiVinTM, Pycnogenol®, and Procydin®. These differ in terms of the source and quantity of 
proanthocyanidin contained as well as in the number and types of other ingredients included. 
We decided to focus our review on Pycnogenol as this is an extensively researched, 
standardised product widely marketed for its antioxidant effects. It should be kept in mind 
that dietary supplements such as Pycnogenol may also have non-antioxidant related activity 
which may account for any observed effects on health. 
 
How the intervention might work  
Three antioxidant mechanisms have been attributed to proanthocyanidin: 
• Free radical scavenging, i.e. proanthocyanidin is oxidized by free radicals, resulting 
in more stable, less-reactive radicals (Cos 2004; Nijveldt 2001); 
• Proanthocyanidin binding of iron and copper, which are cofactors of several enzymes 
involved in oxygen metabolism, thus limiting the formation of free radical reactions 
(Cos 2004); 
• Direct inhibition of pro-oxidative enzymes such as lipoxygenase, nitric oxide synthase 
and xanthine oxidase (Cos 2004). 
 
It is important to recognise that ROS has several important beneficial functions in cells 
including: 
1. Mediation of apoptosis (programmed cell death, also known as cellular suicide); 
2. Mediation of detoxification reactions; 
3. Defending cells against pathogenic viruses and bacteria; 
4. Mediation of other specific biochemical reactions (Salganik 2001; Whitney 2002). 
It is therefore possible that excessive amounts of antioxidants may negatively affect these 
important physiological processes (Bjelakovic 2007). This implies that a balance between 
ROS and antioxidants may be critical for maintaining health. 
 
Why it is important to do this review  
Dietary supplements have expanded into a multi-billion dollar industry worldwide. However, 
the efficacy and safety of antioxidant supplements have not been sufficiently clarified 
(Bjelakovic 2007; Donma 2005; Lichtenstein 2005; Tonks 2007). Pycnogenol is marketed as 
a supplement for preventing the onset, alleviating symptoms or limiting progression of a wide 
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range of chronic clinical disorders. The manufacturer of Pycnogenol strongly promotes 
research and claims that its products are based on results of scientific research (American 
Botanical Council 2010). Although several randomised trials of Pycnogenol have been 
conducted to date, this evidence has not yet been evaluated in a systematic review. 
 
Objectives 
 
To assess the efficacy and safety of Pycnogenol for the treatment of chronic disorders. 
 
Methods 
 
Criteria for considering studies for this review  
Types of studies  
Randomised controlled trials (RCTs) investigating the efficacy or safety (or both) of 
Pycnogenol. 
 
Types of participants  
Adults and children with any chronic disorder, regardless of geographical location or setting. 
We defined a chronic disorder as a disease (e.g. heart disease, stroke, cancer, diabetes, 
HIV/AIDS etc.) or non-specific illness (e.g. fatigue, pain etc.) of more than three months 
duration. 
 
Types of interventions  
Experimental 
Pycnogenol, alone or in combination with other supplements, as long as the comparison 
group(s) received the same treatment apart from Pycnogenol. Any dose or route of 
administration was deemed acceptable, but Pycnogenol should have been used for at least 
one month (four weeks). 
 
Control 
• Placebo; 
• No intervention; 
• Other supplement(s) (excluding those with antioxidant properties). 
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Types of outcome measures  
For each chronic disorder we assessed the following outcomes: 
Primary outcomes  
1. Any clinical outcome directly related to the disorder, stratified as: 
• Participant-reported outcomes (e.g. joint pain in patients with osteoarthritis); 
• Investigator-reported outcomes (e.g. serum cholesterol levels in patients with 
hyperlipidaemia, retinal blood flow with diabetic retinopathy). 
2. All-cause mortality. 
 
Secondary outcomes  
1. Adverse events, stratified as: 
• Serious (causing death, hospitalisation or cessation of use); 
• Not serious. 
2. Biomarkers of oxidative stress (e.g. antioxidant activity in plasma, oxidized glutathione 
concentration). 
Studies reporting only on antioxidant biomarkers were not included. 
 
Search methods for identification of studies  
AS used a comprehensive and exhaustive search strategy in order to identify all relevant 
studies regardless of language or publication status (published, unpublished, in press and in 
progress). 
 
Electronic searches  
Journals and trials databases 
We searched the following databases: 
• MEDLINE (accessed via PubMed), until 18 September 2010; 
• Clinical Trials (CENTRAL) database, The Cochrane Library until 18 September 2010; 
• EMBASE (accessed via Ovid), until 13 October 2010. 
 
Detailed search strategies with the main terms 'Pycnogenol' and 'pine bark', are presented in 
Appendix 1, Appendix 2 and Appendix 3.  
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Trials registries 
The following trial registries were searched for ongoing trials using the phrase "Pycnogenol 
OR pine bark": 
• ClinicalTrials.gov, until 18 September 2010; 
• Current Controlled Trials, until 18 September 2010; 
• World Health Organization (WHO) International Clinical Trials Registry Platform 
(ICTRP), until 18 September 2010. 
 
Searching other resources  
We contacted the manufacturer of Pycnogenol, Horphag Research (UK) Ltd, via email to 
request a list of completed clinical trials. This was received on 21 July 2010. We also hand-
searched the reference lists of included studies in order to identify additional relevant 
studies. 
 
Data collection and analysis  
Selection of studies  
The authors AS and JV independently screened the title and abstract of studies identified by 
the search and applied the pre-specified criteria in order to identify eligible studies. Where at 
least one author considered a study to be relevant, we obtained the full-text and 
independently assessed it for eligibility. Where there was missing information or where 
clarity was needed, we contacted the authors of the primary studies. We resolved any 
remaining disagreement by consensus among the four authors. We listed studies at first 
thought to be relevant but which were later excluded in the table 'Characteristics of excluded 
studies' together with reasons for exclusion. 
 
Data extraction and management  
The authors AS and JV independently extracted data using a standardized, pre-piloted 
extraction form. For each study we collected the following items: administrative details, study 
methodology, participant characteristics, interventions, outcomes, study findings, ethical 
approval and funding sources. The outcomes and results were also independently extracted 
by AM. Disagreements were resolved by consensus. Where reported information was 
unclear or contradictory, or where important data were missing, we contacted the study 
author(s) via email. 
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We planned to group data based on duration of follow-up as follows: 
• Short term (less than three months); 
• Medium term (three months to twelve months); 
• Long term (thirteen months onwards). 
However, this was not done as no study involved a follow-up period of more than three 
months. Where multiple time points were reported for one category (e.g. two week intervals 
for a period of eight weeks of treatment) we used only the longest time point data. 
 
Assessment of risk of bias in included studies  
The authors AS and JV independently assessed each included study for risk of bias using 
the guidelines provided in the Cochrane Handbook of Systematic Reviews of Interventions 
(Higgins 2008). The specific criteria appear in Appendix 4. The components of the 
methodology that were assessed are sequence generation, allocation concealment, blinding, 
incomplete outcome data, selective outcome reporting, and other potential threats to validity. 
Each included study was rated 'yes' (low risk of bias), 'no' (high risk of bias), or 'unclear' 
(uncertain risk of bias) for each of the six domains. Disagreements were resolved by 
consensus. 
 
Crossover trials were additionally assessed, in a separate table (Table 1), to determine 
(Higgins 2008): 
1. Whether the crossover design was suitable; 
2. Whether there was a carry-over effect; 
3. Whether only first period data are available; 
4. Whether a correct analysis (paired analysis) had been used; 
5. Whether the results are comparable to those from parallel-group trials. 
 
Measures of treatment effect  
We used Review Manager Version 5 (RevMan 2008) to conduct the analyses. We calculated 
risk ratios (RRs) for dichotomous data and mean differences (MDs) for continuous data. All 
results are presented with 95% confidence intervals except where data were reported as 
medians and ranges. Where results were reported insufficiently for analysis (e.g. where 
standard deviation (SD) of change was not provided and the contact authors of the studies 
have not yet responded to our requests), we presented the available results in a table. 
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Unit of analysis issues  
The two crossover trials in the included studies were not included in any meta-analysis as 
one did not report results for the placebo group and the other reported results insufficiently. 
One included study had three intervention groups (local plus oral Pycnogenol; oral 
Pycnogenol; local Pycnogenol) and one control group (no treatment). Since the intervention 
group of all the other included studies involved oral Pycnogenol only, we decided to select 
this group from the above trial and exclude the other two groups from the analysis. 
 
Dealing with missing data  
We attempted to obtain essential missing data by contacting the original authors whenever 
possible (Appendix 5). Where there was no missing data we used the intention-to-treat 
principle. In the presence of missing dichotomous data we still used the intention-to-treat 
principle but assumed that the missing participants did not experience the event. In the case 
of missing continuous data we used the available-case analysis. 
 
Assessment of heterogeneity  
We assessed heterogeneity in our two meta-analyses using visual inspection of the forest 
plots. If confidence intervals for the results of individual studies had poor overlap, we took 
this as an indication of statistical heterogeneity. Furthermore, we used the Chi2 test for 
heterogeneity (significance level P < 0.1) and quantified the degree of heterogeneity by 
means of the I2 statistic (Higgins 2003). The following guidelines were used for the 
interpretation of the I2 values (Higgins 2008): 
• 0% to 40%: might not be important; 
• 30% to 60%: may represent moderate heterogeneity; 
• 50% to 90%: may represent substantial heterogeneity; 
• 75% to 100%: considerable heterogeneity. 
 
Assessment of reporting biases  
It was not appropriate to draw funnel plots as the number of studies was insufficient. 
Therefore it was not possible to explore the possibility of small study bias. 
 
Data synthesis  
We used a fixed effects model to combine the results of studies where appropriate.  Only 
two studies presented outcomes that allowed for pooling of results. However, should 
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considerable statistical heterogeneity (I2  75%) existed we would not have pooled the study 
results in a meta-analysis but reported it separately.  
 
Subgroup analysis and investigation of heterogeneity  
We planned to further investigate statistical heterogeneity by conducting the following 
subgroup analyses: 
• Age: adults (over 16 years versus children (16 years and younger); 
• Dose of Pycnogenol used: high dose (150 mg/day and above) versus low dose (up 
to 150 mg/day); 
• Type of disorder (e.g. cardiovascular disease, cancers, chronic obstructive 
pulmonary disease, metabolic disorders). 
However, the data available was insufficient to undertake subgroup analysis. 
 
Sensitivity analysis  
We planned to perform a sensitivity analysis if appropriate in order to assess the influence of 
study quality (using adequacy of allocation concealment as a marker) and funding source on 
the findings. Due to insufficient data this was not possible in this review, but may be 
appropriate in future updates. 
 
Results 
 
Description of studies  
Results of the search  
Figure 1 summarises the search results. In total we screened 246 records of which 36 were 
identified as potentially eligible. The full-text articles of these were obtained for further 
assessment. Fifteen studies met our eligibility criteria and the rest were excluded with 
reasons which are displayed in the table of 'Characteristics of excluded studies'. Another 
completed study is awaiting classification as the information from this study is currently 
available only as a conference abstract and poster (see table of 'Characteristics of studies 
awaiting classification'). We identified four ongoing studies, the available details of which are 
provided in the table of 'Characteristics of ongoing studies'. 
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Included studies  
Fifteen RCTs with a total number of 791 participants were included in the review and full 
details of these studies are provided in the table 'Characteristics of included studies'. All 
studies employed a parallel group design, except for Hosseini 2001a and Hosseini 2001b 
which were crossover trials. The studies assessed the effects of Pycnogenol in patients 
suffering from seven different chronic disorders: 
• Asthma: two trials with a total of 86 participants conducted in Iran and the USA 
(Hosseini 2001a, Lau 2004); 
• Attention deficit hyperactivity disorder (ADHD): one study with 61 participants 
conducted in Slovakia (Trebatická 2006); 
• Chronic venous insufficiency (CVI): two trials with a total of 60 participants both 
conducted in Italy (Arcangeli 2000, Petrassi 2000); 
• Diabetes mellitus: four trials with a total of 201 participants conducted in Italy (2), 
China and the USA (Belcaro 2006a, Liu 2004a, Steigerwalt 2009, Zibadi 2008); 
• Erectile dysfunction (ED): one study with 21 participants conducted in Slovak 
Republic (Duracková 2003); 
• Hypertension: two trials with a total of 69 participants conducted in the USA and 
China (Hosseini 2001b, Liu 2004c); 
• Osteoarthritis: three trials with a total of 293 participants conducted in Slovakia, Iran 
and China (Belcaro 2008b, Cisár 2008, Farid 2007).   
 
Two of the 15 studies were conducted exclusively in children (Lau 2004, Trebatická 2006); 
the rest included only adults. In all studies Pycnogenol was consumed orally, except for 
Belcaro 2006a in which Pycnogenol was also applied locally to skin ulcers. The duration 
and dosages varied across studies and chronic conditions: 
• Asthma: in both studies the dosage of Pycnogenol depended on individual body 
weight (1 mg/lb/day). In Hosseini 2001a the treatment duration was four weeks while 
in Lau 2004 it was three months. 
• ADHD: dosage of Pycnogenol depended on individual body weight (1 mg/kg/day); 
treatment duration was one month. 
• CVI: in both studies participants received 300 mg Pycnogenol per day; treatment 
duration was two months. 
• Diabetes mellitus: treatment duration in Belcaro 2006a was six weeks; there were 
three treatment groups. The group that received Pycnogenol orally got 150 mg/day 
and the group that applied Pycnogenol locally used 100 mg/day; the third group (oral 
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plus local Pycnogenol) thus used a total of 250 mg Pycnogenol daily. The treatment 
duration in Liu 2004a and Zibadi 2008 was 12 weeks and the participants consumed 
100 mg and 125 mg Pycnogenol per day respectively. The participants in 
Steigerwalt 2009 received 150 mg Pycnogenol daily for two months. 
• ED: the Pycnogenol group consumed 120 mg Pycnogenol daily for three months. 
• Hypertension: the treatment period in Hosseini 2001b was eight weeks compared to 
12 weeks in Liu 2004c. Participants in Liu 2004c received 100 mg Pycnogenol per 
day and those in Hosseini 2001b twice as much. 
• Osteoarthritis: in Cisár 2008 and Farid 2007 the participants in the Pycnogenol 
group received 150 mg Pycnogenol daily, while those in Belcaro 2008b received 100 
mg/day. The treatment duration in all three studies was three months. 
 
Excluded studies  
Eighteen studies were excluded with reasons (see the table 'Characteristics of excluded 
studies'). The most common reason for exclusion was that the study was not randomised 
(8/18). Other reasons were: the treated condition was not a chronic disorder (2/18), 
prevention rather than treatment (2/18), an inappropriate control group (4/18) and 
inappropriate outcomes (2/18). 
 
Risk of bias in included studies  
Our judgements regarding the risk of bias in each of the included studies can be found in the 
table 'Characteristics of included studies'. Figure 2 and Figure 3 provides a graphical 
summary of the risk of bias assessments. Table 1 presents additional information regarding 
the risk of bias in the two crossover trials included in the review (Hosseini 2001a, Hosseini 
2001b). 
 
Allocation  
Allocation refers to both the generation of the random allocation sequence and concealment 
of the allocation code.  
 
While all included trials reported that allocation had been randomised, the method used for 
generating the allocation sequence was judged to be adequate in only five (Belcaro 2008b, 
Hosseini 2001b, Petrassi 2000, Steigerwalt 2009, Trebatická 2006). The other ten studies 
provided insufficient information regarding this component of the study design. 
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None of the included trials described the method used for concealing allocation except for 
Lau 2004. In this study the authors reported that the treatment was "identified by 
preassigned codes prepared by an independent laboratory" but the coding is not described. 
The risk of bias for all 15 studies was therefore judged as 'unclear'. 
 
Blinding  
Fourteen included trials were reported to be "double-blind". However, only three (Lau 2004, 
Petrassi 2000, Trebatická 2006) mentioned who was blinded (e.g. participants, providers or 
outcome assessor) or that the placebo was indistinguishable from the test drug. Therefore 
we judged these three studies to have a low risk of bias. 
 
Eleven studies were judged as having an unclear risk of bias. Of these, five (Arcangeli 2000, 
Belcaro 2008b, Cisár 2008, Farid 2007, Zibadi 2008) reported that the placebo was identical 
to the test drug in terms of appearance. However, it is not clear whether the placebo was 
also matched in terms of other characteristics such as weight and taste. Pycnogenol is 
known to have a bitter, astringent taste. The other six studies provided no further details 
other than the use of a double-blind design (Hosseini 2001a, Hosseini 2001b, Liu 2004a, Liu 
2004c, Steigerwalt 2009, Duracková 2003). 
 
In Belcaro 2006a blinding did not occur because of the nature of the interventions. There 
were four groups in this study: one group consumed Pycnogenol orally, the second group 
applied Pycnogenol locally (on the ulcer), the third group used Pycnogenol both orally and 
applied it locally while the fourth group did not receive any medical treatment. This study is 
judged to have a high risk of bias. 
 
Incomplete outcome data  
Seven of the 15 included trials were judged to have adequately addressed incomplete 
outcome data because no participants were lost to follow-up during the study period (Belcaro 
2006a, Hosseini 2001b, Liu 2004a, Liu 2004c, Petrassi 2000, Steigerwalt 2009, Duracková 
2003). In Cisár 2008 more than twice as many participants were lost to follow-up in the 
control group than in the group receiving the test drug. Therefore this study was judged to 
have a high risk of bias. 
 
The remaining seven included trials were judged as having an unclear risk of bias. In three 
studies (Farid 2007, Trebatická 2006, Zibadi 2008) an "intention-to-treat" analysis was 
performed. However, it is not clear what the authors mean by the term e.g. whether missing 
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data were imputed. The other four studies that were judged as unclear are Arcangeli 2000, 
Belcaro 2008b, Hosseini 2001a, and Lau 2004. Hosseini 2001a used a crossover design but 
it is not reported whether the analyses were performed with first or second period data or 
both, or how participants who were lost to follow-up were dealt with in the analysis. In 
Arcangeli 2000 and Lau 2004 it is not reported whether all randomised participants 
completed the study and whether analyses were done on data from all outcomes for all 
participants. In Belcaro 2008b it is stated that 11 participants were lost to follow-up but it is 
not reported how this was addressed in the analysis. 
 
Selective reporting  
The protocol for each included trial was searched for in the trials registries mentioned under 
'Search methods for identification of studies'. Studies that do not have a protocol available 
can at best be judged as having an unclear risk of bias with regards to selective reporting. 
This was the case in all studies except Zibadi 2008. In addition, we assessed whether 
reports stated the pre-specified study outcomes in the Methods section and judged those 
that did not as having a high risk of bias. This was the case in 13 studies (all except for Cisár 
2008 and Hosseini 2001a which pre-specified their outcomes). All outcomes pre-specified in 
Zibadi 2008's protocol were addressed in the study, but there were outcomes reported in the 
study that were not pre-specified in the protocol. No outcomes were reported in the Methods 
section of the study. This trial was judged to have a high risk of bias. 
 
Other potential sources of bias  
For the judgement of this domain, we focused on the reporting of baseline characteristics 
(not relevant for the two crossover studies) and source of funding. 
 
All studies except Duracková 2003 reported baseline characteristics separately for the 
treatment and control groups and we therefore judged them to have a low risk of bias. 
Duracková 2003 was judged to have an unclear risk of bias because the age of the 
participants was not reported separately for the treatment and control groups.  
 
Horphag Research Ltd, the manufacturer and holder of Pycnogenol's registered trademark, 
funded seven of the studies included in this review (Belcaro 2006a, Cisár 2008, Farid 2007, 
Hosseini 2001b, Lau 2004, Trebatická 2006, Zibadi 2008). These were judged to have an 
unclear risk of bias. The source of funding was not reported in six of the included studies 
(Arcangeli 2000, Belcaro 2008b, Liu 2004a, Liu 2004c, Petrassi 2000, Steigerwalt 2009) and 
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they were also judged as having an unclear risk of bias. Hosseini 2001a was funded by 
companies other than Horphag Research Ltd and was judged to have a low risk of bias. 
 
Effects of interventions  
We grouped the included studies according to the type of chronic disorders involved and 
reported findings for the outcomes as pre-specified in our review protocol, when available. 
Our primary outcome 'all-cause mortality' was not addressed in any of the studies. While we 
would have liked to report on the change in symptoms or signs from baseline for several 
outcomes, this was often not possible as studies did not provide the information required to 
calculate this (e.g. SD of change). In such cases, if the baseline characteristics were 
balanced across the comparison groups, we assessed the difference in outcomes at the end 
of treatment. This is not ideal since the studies are all small (ranging from 11 to 156 
participants). Furthermore, in some studies key results were missing from some or all 
relevant outcomes, for example results were reported only for the treatment group but not for 
controls, or no measure of variation (or exact p-value) was reported to allow for calculation of 
SD. Outcomes for which results are in part missing and estimates of effect that could not be 
calculated are presented in additional tables which show only the results as reported in the 
studies (Table 2; Table 3; Table 4; Table 5; Table 6; Table 7; Table 8; Table 9; Table 10; 
Table 11; Table 12; Table 13; Table 14). 
 
Efficacy: Asthma 
One crossover study (N = 26) conducted in Iran assessed the effect of four weeks treatment 
with Pycnogenol versus placebo in adults (Hosseini 2001a). In another study (parallel group 
design, N = 60) in the USA, Pycnogenol was compared with placebo in children over a 
period of three months (Lau 2004). 
 
Participant-reported clinical outcomes 
Asthma symptom scores were measured by both Hosseini 2001a and Lau 2004, but due to 
insufficient information results could not be evaluated (Table 2). We have contacted the 
study authors for additional information and are awaiting their response. In Lau 2004 all 30 
participants in the Pycnogenol group reported a decrease in asthma symptoms at the end of 
the treatment period compared to 16/30 in the control group, risk ratio (RR) 1.85 (95% CI 
1.32 to 2.58). In the same study the number of participants who stopped use of an albuterol 
inhaler at the end of the treatment period was 18/30 in the Pycnogenol and 3/30 in the 
control group (RR 6.0; 95% CI 1.97 to 18.25). The mean number of albuterol inhaler puffs 
per 24 hours was also measured in Lau 2004. The SD of change was not provided; we've 
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contacted the study authors and are awaiting their response. We could however compare 
the final values (at the end of the three months treatment period) and found that a 
significantly lower number of puffs were needed per 24 hours with Pycnogenol compared to 
placebo, mean difference (MD) -2.1 (95% CI -2.53 to -1.67). The baseline values were 
similar (Table 2). 
 
Investigator-reported clinical outcomes 
Peak expiratory flow was measured in Lau 2004, but results were not evaluable (Table 2). 
We have contacted the authors for additional information and are awaiting their response. In 
Hosseini 2001a there was a statistically significant improvement in pulmonary function at the 
end of the one month treatment period when comparing Pycnogenol with placebo. The MD 
for the forced expiratory volume in one second (FEV1) was 7.0 (95% CI 0.10 to 13.90) and 
for FEV1/forced vital capacity (FVC) the MD was 7.70 (95% CI 3.19 to 12.21). 
 
Efficacy: Attention deficit hyperactivity disorder 
One study (N = 61) in which Pycnogenol versus placebo treatment was given to children for 
a month was conducted in Slovakia (Trebatická 2006). 
 
Participant-reported clinical outcomes 
Parents and teachers evaluated hyperactivity and inattention: teachers by means of CAP 
(Child Attention Problems Teacher Rating Scale) and CTRS (Conner's Teacher Rating 
Scale) and parents by means of CPRS (Conner's Parent Rating Scale). Results were only 
reported in a figure together with exact p-values comparing final values (end of month one) 
of Pycnogenol versus placebo. Since the baseline CAP scores (inattention and hyperactivity) 
of the Pycnogenol and placebo groups were the same, and the percentage change at the 
end of the one month treatment period relative to baseline was reported for CTRS, we could 
compare the change in each group for these two outcomes. However, for CPRS only the 
final values could be compared. We've contacted the authors for additional information and 
are awaiting their response. In the mean time, where relevant, we've extracted the mean 
scores or percentages from the figures and used the p-values to calculate the relevant 
standard errors. A decrease in CAP, CTRS and CPRS represent an improvement in 
inattention and hyperactivity. The Pycnogenol group reported a significant improvement in 
inattention at the end of treatment compared to control [CAP score MD 2.0 (95% CI 0.61 to 
3.39); CTRS (% change) MD 14.0 (95% CI 0.34 to 27.66)]. With regards to the CPRS score 
for inattention, the study only reported that non-significant changes occurred in both groups. 
The Pycnogenol group also reported an improvement in hyperactivity compared to control, 
but this was only statistically significant for CAP [CAP score MD 2.0 (95% CI 0.10 to 3.90)] 
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and not for CTRS (% change) MD 4.0 (95% CI -3.19 to 11.19). The difference in end of 
month one CPRS scores between the Pycnogenol and placebo groups was not significant, 
MD -3.50 (95% CI -7.15 to 0.15). 
 
Investigator-reported clinical outcomes 
Psychologists evaluated the children's visual-motoric coordination and concentration and 
found an improvement with Pycnogenol (MD 8.0; 95% CI 0.16 to 15.84). 
 
Biomarkers of oxidative stress 
Glutathione formed from amino acids in human cells can occur either in a reduced (GSH) or 
oxidized form (GSSG). A decrease in oxidative stress will be reflected in an increased 
GSH/GSSG. The percentage change in GSH/GSSG was obtained from Dvoráková 2007 
which reports on the same study as Trebatická 2006. Results were not reported sufficiently 
to calculate an effect size (Table 3); study authors have been contacted and we are awaiting 
their response. 
 
Efficacy: Chronic venous insufficiency 
In two studies (Arcangeli 2000 N = 40; Petrassi 2000 N = 20) conducted in Italy, adults were 
treated with Pycnogenol versus placebo for a period of two months (60 days). 
 
Participant-reported clinical outcomes 
Both studies evaluated the change in scores of heaviness, swelling and pain of the legs by 
using the same four-point symptom scale where 0 = symptom absent and 3 = symptom 
severe (see table of 'Characteristics of included studies'). While Petrassi 2000 stated in their 
Methods section that they also evaluated the change in scores for the symptoms night 
cramps and paraesthesiae, no results for these two symptoms were reported. We have 
contacted the study authors for this information and are awaiting their response. 
 
Because the SD of change is not provided in either study we could not compare the change 
in symptoms in the comparison groups (Table 4). We have contacted the corresponding 
author of Petrassi 2000 and are awaiting their response; the author of Arcangeli 2000 is not 
contactable. We conducted a meta-analysis of the final results (end of month two) of the two 
studies (60 participants). The heaviness score (MD -0.72; 95% CI -0.91 to -0.54; fixed effect, 
heterogeneity Chi2 = 0.0, I2 = 0%) (Analysis 3.1; Figure 4) as well as swelling (MD -0.46; 95% 
CI -0.67 to -0.25; fixed effect, heterogeneity Chi2 = 2.31, I2 = 57%) (Analysis 3.2; Figure 5) 
was significantly lower in the Pycnogenol group compared to placebo. Pains scores in 
Arcangeli 2000 were also lower with Pycnogenol (MD -0.59; 95% CI -1.02 to -0.16). Petrassi 
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2000 reported that "the pain parameter could not be evaluated because of the small number 
of participants who showed a positive score". It is important to note that when comparing 
only final values (and not the change in each group) it is assumed that the baseline values 
are balanced which would be expected to be the case in RCTs that are sufficiently large. 
This was not the case in Arcangeli 2000 and Petrassi 2000. In Arcangeli 2000 heaviness 
score was 19.8% greater, legs were 12% more swollen and patients experienced 13.4% 
more pain at baseline in the Pycnogenol group compared to placebo. In Petrassi 2000 mean 
heaviness score was 21.3% greater and there was 25% more leg swelling in the Pycnogenol 
group. Baseline values for pain were not reported in this study. 
 
Both studies reported the percentage of participants that had disappearance of the 
symptoms heaviness and swelling at the end of the treatment period, and Arcangeli 2000 
also reported on pain. However, only effect sizes for Arcangeli 2000 could be calculated 
because Petrassi 2000 did not report results for the placebo group. We have contacted the 
study authors for this information and are awaiting their response. In Arcangeli 2000 the RR 
for disappearance of heaviness was 15.0 (95% CI 0.91 to 246.20), disappearance of 
swelling (27.0; 95% CI 1.71 to 425.36) and disappearance of pain (25.0; 95% CI 1.58 to 
395.48) in the Pycnogenol group versus the placebo. 
 
Investigator-reported clinical outcomes 
In Arcangeli 2000 physicians judged the efficacy of the treatment on a pre-specified scale 
where 1 = poor and 4 = very good. We found Pycnogenol to be significantly more efficacious 
compared to placebo (RR 4.75; 95% CI 1.97 to 11.48). This same outcome was assessed in 
Petrassi 2000 but the combined result of both the randomised and non-randomised arm of 
the study was reported. This was also the case for the other eligible outcome namely change 
in ambulatory venous pressure. We've contacted the study authors for the additional 
information we require and are awaiting their response. Arcangeli 2000 measured venous 
blood flow and reported simply that no difference in either of the groups was found at the 
end of the treatment period compared to baseline. 
 
Efficacy: Diabetes mellitus 
Four studies (N = 201) were performed on adults with diabetes (Belcaro 2006a, Liu 2004a, 
Steigerwalt 2009, Zibadi 2008) but none of them had the same primary outcomes. Belcaro 
2006a conducted a study in Italy on 30 insulin-dependent diabetics. They evaluated the 
effect of Pycnogenol (orally, locally, and both orally and locally) versus no medical treatment 
on foot ulcers for six weeks. In Liu 2004a the effect of a 12 week Pycnogenol versus placebo 
treatment on blood glucose levels was assessed in China on 77 type II diabetics. Steigerwalt 
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2009 conducted a study in Italy evaluating the two months treatment effect of Pycnogenol 
versus placebo on retinopathy in 46 type II diabetics, whereas Zibadi 2008 assessed the 
effect of a 12 week Pycnogenol versus placebo treatment on 48 hypertensive type II 
diabetics in the USA. 
 
Participant-reported clinical outcomes 
In Belcaro 2006a participants reported on the change in symptoms related to the 
microcirculation where a score of 0 represents absence of symptoms and a score of 10 very 
severe symptoms. The SD of change was not given (we have contacted the study authors 
and await their response), hence we used the final values (Table 5). The baseline values 
were similar (Table 5). This study had three intervention groups (local plus oral Pycnogenol; 
oral Pycnogenol; local Pycnogenol) and one control group (no treatment). Since the 
intervention group of all the other included studies involved oral Pycnogenol, we decided to 
select this group and exclude the other two groups from the analysis. The microcirculation-
related symptoms were not significantly lower in the Pycnogenol group compared to the 
control, MD -1.30 (95% CI -4.02 to 1.42). 
 
Steigerwalt 2009 assessed the change in visual acuity as subjectively reported by 
participants. However, no results for the placebo group are reported. We have contacted the 
study authors and are awaiting their response. 
 
Investigator-reported clinical outcomes 
In Belcaro 2006a the final values of area of ulceration (mm2) for Pycnogenol (oral) were not 
significantly lower compared to control, MD -4.0 (95% CI -9.92 to 1.92). However, the 
transcutaneous PO2 (mm Hg) was significantly higher in the Pycnogenol (oral) group 
compared to the control (MD 7.0; 95% CI 3.18 to 10.82) but not significantly lower for 
transcutaneous PCO2 (mm Hg) (MD -1.0; 95% CI -3.79 to 1.79). Results for the outcome 
skin flux at rest were reported insufficiently (Table 5); we have contacted the study authors 
and are awaiting their response. The outcome venoarteriolar response (LDF units) was 
reported in medians and ranges (Table 6). 
 
Liu 2004a measured the change in blood glucose (mmol/l) and plasma HbA1c (%) between 
baseline and week 12 and analysed it with the Mann-Whitney rank sum test. The results of 
this change were therefore reported as medians and interquartile ranges (Table 7). 
 
Zibadi 2008 also measured change in blood glucose (mg/dl) and HbA1c (%), and in addition 
urinary albumin levels (mg/l) (Table 8). Because the SD of change was not reported (we've 
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contacted the study authors for this information and are awaiting their response), we 
compared the final values (end of week 12) of the two groups. Blood glucose levels in the 
Pycnogenol group were not significantly lower compared to control (MD -26.70; 95% CI -
55.79 to 2.39). Baseline values were not quite balanced as glucose levels (mg/dl) in the 
Pycnogenol group was 6.8% less compared to placebo. Furthermore, in Zibadi 2008 the 
HbA1c was lower in the Pycnogenol versus placebo group at the end of week 12 (MD -0.9; 
95% CI -1.78 to -0.02) but urinary albumin levels was not significantly lower (MD -13.90; 
95% CI -31.09 to 3.29). The mean HbA1c at baseline in the Pycnogenol group was 2.5% less 
than placebo while the mean urinary albumin value at baseline were 20.8% less than 
placebo. 
 
In Steigerwalt 2009 change in visual acuity was also evaluated using a Snellen chart. 
However, the results were reported separately for participants with moderate and mild 
edema (not pre-specified in the Methods section), thereby making it impossible to compare 
Pycnogenol and placebo for all randomised participants. For the same reason we could not 
analyse results for the outcomes change in retinal blood flow, diastolic blood flow relative to 
maximum systolic blood flow, retinal edema score and retinal thickness. We have contacted 
the study authors for the required information and are awaiting their response. 
 
Biomarkers of oxidative stress 
The concentration of nitric monoxide (nmol/l), a type of free radical that also has important 
functions in the body such as vasodilation, was measured in Liu 2004a. No results were 
reported, only that the difference between Pycnogenol and placebo was not statistically 
significant. 
 
Efficacy: Erectile dysfunction 
One small study (N = 21) conducted in Slovak Republic assessed the effect of three months 
treatment with Pycnogenol versus placebo in adult men (Duracková 2003). 
 
Participant-reported clinical outcomes 
ED symptom scores were measured with the help of the International Index of Erectile 
Function (IIEF-5) questionnaire (maximum score = 25; normal erectile function scores 
between 21 and 25) (see the table 'Characteristics of included studies'). The SD of change 
was not reported (Table 9). We have contacted the study authors for this information and are 
awaiting their response. Comparing the final values (end of month three) we found a 
significantly higher score with Pycnogenol treatment, MD 7.90 (95% CI 5.08 to 10.72). 
Comparison of the baseline mean ED symptom scores showed an 11.5% higher score in the 
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Pycnogenol group compared to placebo. A further reason for caution is the lack of 
comparative baseline data regarding age of participants which could be a potential 
confounder in ED studies. 
 
Biomarkers of oxidative stress 
Antioxidant activity in the blood was measured but results were not reported sufficiently 
(Table 9). We have contacted the authors for additional information and are awaiting their 
response. 
 
Efficacy: Hypertension 
Two studies with a total of 68 participants - Hosseini 2001b (crossover trial; USA; N = 11) 
and Liu 2004c (parallel-group trial; China; N = 58) - investigated the treatment effect of 
Pycnogenol versus placebo for a period of eight and 12 weeks respectively, in adults. 
 
Investigator-reported clinical outcomes 
Change in blood pressure was only measured directly by Hosseini 2001b; however no 
results were reported for the placebo group (Table 10). In Liu 2004c blood pressure changes 
were indirectly evaluated by monitoring the nifedipine dose needed to control participants' 
blood pressure. All participants received 20 mg nifedipine at the start of the treatment period 
and adjustments to the dose was made as necessary at each visit. The number of 
participants who used a reduced nifedipine dose at the end of the treatment period (week 
12) was not significantly higher in the Pycnogenol group compared to placebo (RR 1.12; 
95% CI 0.83 to 1.52). However, the number of participants in the Pycnogenol group who 
reduced nifedipine dose to 10 mg at the end of the 12th week of treatment was significantly 
higher compared to placebo (RR 4.29; 95% CI 1.63 to 11.27). 
 
Biomarkers of oxidative stress 
The concentration of nitric monoxide was measured in Liu 2004c; results were reported as 
medians and interquartile ranges (Table 11). 
 
Efficacy: Osteoarthritis of the knee 
In three studies with a total of 293 participants (Belcaro 2008b N = 156; Cisár 2008 N = 100; 
Farid 2007 N = 37) adults were treated with Pycnogenol versus placebo for a period of three 
months (12 weeks or 90 days). The studies were conducted in Italy, Slovakia and Iran 
respectively. 
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Participant-reported clinical outcomes 
All three studies evaluated the effect of Pycnogenol on pain, stiffness, physical function 
(referred to as 'daily activities' in Cisár 2008) and overall effect by means of WOMAC 
(Western Ontario and McMaster Universities) scores. Additionally, in Belcaro 2008b, 
negative alterations in social functions and the sum of emotional parameters were also 
evaluated as osteoarthritis symptoms with the WOMAC instrument. According to Bellamy 
2001 the WOMAC instrument is available either in a Likert scale or in a visual analogue 
format. Cisár 2008 used a Likert scale and Farid 2007 a visual analogue scale (VAS). It is 
not reported what type of scale Belcaro 2008b used, but the interpretation of the scale is 
reported (see ‘Characteristics of included studies’). The results of these three studies could 
not be pooled due to Cisár 2008 who reported results in median WOMAC scores and 
Belcaro 2008b and Farid 2007 who reported the results insufficiently (Table 12). However, in 
Farid 2007, the final values of each group (end of month three) could be compared. Pain 
scores (MD -142.0; 95% CI -199.55 to -84.45), physical function scores (MD -529.0; 95% CI 
-741.59 to -316.41) and composite WOMAC scores (MD -730.0; 95% CI -1011.95 to -
448.05) were significantly lower in the Pycnogenol group compared to placebo. However, 
stiffness scores were not significantly lower (MD -33.0; 95% CI -68.48 to 2.48). Inspecting 
the baseline values indicated that the Pycnogenol group had 3% less pain, 8.3% less 
stiffness, 4.3% less physical function and had overall 4.3% less osteoarthritis symptoms than 
the placebo group. In Cisár 2008 medians were presented graphically together with p-values 
but no range were reported to indicate the spread (Table 13). We have contacted the study 
authors for this information and are awaiting their response. 
 
Change in the use of concomitant medication [or specific concomitant medication such as 
nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 inhibitors (COX-2)] 
was monitored in each of the three studies. In Belcaro 2008b results for the reduction of 
NSAIDs use was reported as 58% for the Pycnogenol and 1% for the placebo group. We 
have contacted the study authors for clarification and interpretation of this outcome and are 
awaiting their response. Cisár 2008 reported that 38% in the Pycnogenol and 8% in the 
placebo group (50 participants in both groups) used a decreased analgesic dosage at the 
end of the three months treatment period, compared to start. This translates into a significant 
difference of 19/50 versus 4/50 events, RR 4.75 (95% CI 1.74 to 12.97). Farid 2007 reported 
on the change in frequency and dosage of NSAIDs and COX-2 inhibitor usage during the 
treatment period. Results were reported only in a figure from which we could not extract data 
accurately; we have contacted the study authors for the required information and are 
awaiting their response. 
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Investigator-reported clinical outcomes 
In Belcaro 2008b physical performance at baseline and after three months of treatment was 
evaluated on a treadmill. Results were reported as means and ranges (Table 14). 
 
Safety 
Results for safety of the treatment across all seven chronic disorders, stratified as serious 
and non-serious, are presented in Table 15. None of the fifteen included studies assessed 
safety as a main outcome. All of the studies, except Duracková 2003 (which did not assess 
this outcome), evaluated safety of the treatment by asking participants to report on adverse 
events they experienced during the treatment period, and/or by reports from the caretaker (if 
participants were children) or investigator, and/or by analysing the levels of various 
biochemical parameters in order to assess whether or not the levels stayed within the range 
of physiological values during the treatment period. 
 
Cessation of treatment use was classified as a serious adverse event. The only study that 
clearly reported that the reason for withdrawal from the study was related to the received 
treatment was Cisár 2008 where 2/50 participants from the Pycnogenol group left compared 
to 5/50 from the placebo group. 
 
Non-serious adverse events were reported in the following studies: Hosseini 2001a, Liu 
2004a, Liu 2004c, Trebatická 2006. The most frequently found adverse event was gastro-
intestinal discomfort. 
 
Discussion 
 
Summary of main results  
Our objectives were to assess both the efficacy and safety of Pycnogenol for the treatment 
of chronic disorders. The main finding of this review is that the current evidence-base is both 
incomplete and inadequate and therefore definitive conclusions about the effects of this 
intervention are not possible at this stage. 
 
Overall completeness and applicability of evidence  
Only fifteen studies, comprising 791 participants, were eligible for inclusion in this review. 
These addressed seven different disorders. Even for the same disorder outcomes assessed 
either differed, were measured in different ways or failed to provide sufficient information to 
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conduct an appropriate analysis. Sample size per study ranged from 11 to 156 participants. 
A major problem with small studies is that findings are unreliable due to the play of chance. 
Moore 1998 demonstrated that for results to be statistically accurate and clinically relevant a 
researcher requires nearly 500 people per group which can be obtained by either conducting 
such large trials or by pooling results from multiple studies of small size. They stress that 
single small trials are highly likely to provide misleading results. Thus despite the apparent 
positive findings of studies in this review the small sample size per study and limited number 
of studies per disorder precludes firm conclusions regarding the effects of Pycnogenol. 
 
Another complicating issue is the heterogeneity in the way outcomes are presented across 
studies. In general, with the exception of participant-reported symptom scores, the outcomes 
per disorder varied across the different studies making it impossible to pool results from 
different studies. In some cases outcomes were not measured in an optimal manner. For 
example, in one of the two studies on hypertension, systolic and diastolic blood pressure 
was not reported directly but by the change in nifedipine dosage at the end of the treatment 
period, compared to baseline. Achieving standardisation of outcomes in trials that evaluate 
the same intervention for the same condition should be an important goal (Clarke 2007). 
Examples of such initiatives exist for cancer, rheumatology and chronic pain (Clarke 2007). 
Similarly the dosage and duration of Pycnogenol treatment across studies should be 
standardised. 
 
Lastly, all studies were conducted in affluent countries and it is therefore not known to what 
extent the results can be applied to people in developing countries. 
 
Quality of the evidence  
A major problem with the current evidence-base is the potential risk of bias across studies 
(Figure 3). It is worth mentioning that the overall quality of reporting was poor which made 
judgements about study quality difficult. We have contacted authors of all of the included 
studies (except for one study of which the authors passed away) to ask for additional 
information (Appendix 5). We await their response which will hopefully allow us to make 
clearer judgements about the risk of bias. 
 
Potential biases in the review process  
It is unlikely that we have missed any relevant RCTs that have assessed the clinical efficacy 
or safety of Pycnogenol since apart from our electronic and manual searches we have 
contacted and obtained information about studies from the manufacturer of Pycnogenol. No 
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language restriction was applied to studies considered for our review. We included adults 
and children with any chronic disorder and used wide criteria for interventions and outcomes. 
 
Our review highlights the inadequate reporting of study details by authors which makes 
judgements of study quality challenging. Reporting standards such as the Consolidated 
Standards of Reporting Trials (CONSORT) have been established for reporting studies and 
journal editors should ensure that these are applied as a condition for publishing.  
 
We were unable to formally assess the likelihood of publication bias (selective reporting of 
positive findings) in this review as this was not possible due to the small number of studies 
per condition. However, as publication bias is more likely with small studies this could be a 
possible explanation of the positive findings seen in the studies we identified. 
 
Agreements and disagreements with other studies or reviews  
This is the first systematic review to specifically evaluate Pycnogenol's efficacy and safety 
for the treatment of chronic disorders. However, three systematic reviews explored the use 
of a variety of supplements, including Pycnogenol, on type II diabetes, asthma and 
osteoarthritis respectively (Bartlett 2008; Clark 2010; Henrotin 2010). 
 
Bartlett 2008 examined the effects of nutritional supplementation for the treatment of type II 
diabetes. Of the three studies focusing on Pycnogenol only Liu 2004a was included in our 
review. Another study Spadea 2001 did not meet our eligibility criteria because the results 
for randomised participants were not reported separately (see table of 'Characteristics of 
excluded studies'). An additional article authored by W. Leydhecker in 1986 seems to be an 
unpublished study from the University Clinic of Wurzburg (Germany). Although we didn't 
come across this study in our search, this study was ineligible for inclusion in our review 
since the control Dexium has antioxidant properties. Bartlett 2008 only presented the 
findings as reporting in these studies and did not attempt to recalculate the estimates or 
synthesise the results quantitatively.  
 
Clark 2010 assessed the efficacy of herb and plant extracts, including Pycnogenol, in the 
management of asthma. Two studies with Pycnogenol as the intervention were included 
(Hosseini 2001b; Lau 2004) and both are included studies in our review as well. Like us 
Clark 2010 noted the problem with variation in outcome measures across different studies. 
As an example they pointed out that FEV1 was measured in five different ways across 17 of 
their included studies. In the two Pycnogenol studies Clark 2010 calculated an effect size for 
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the use of albuterol inhaler by measuring the number of puffs needed per 24 hours at the 
end of the treatment period and got the same results as we did. Regarding the risk of bias 
assessments Clark 2010 assessed only sequence generation, allocation concealment and 
blinding. For Hosseini 2001b their judgements were the same as ours but for Lau 2004 they 
judged allocation concealment as adequate compared to ours which was 'unclear'.  
 
Henrotin 2010 aimed to "synthesize and evaluate scientific relevant data" on nutraceuticals 
that can "support health and physiological or functional benefit on osteoarthritis". Four 
clinical trials of Pycnogenol were included, three of which we have as included studies 
(Belcaro 2008b; Cisár 2008; Farid 2007). We excluded Belcaro 2008a as this reported on a 
non-random subsample of trial participants (see table of 'Characteristics of excluded studies' 
for reason of exclusion). Henrotin 2010 only stated what was reported in the various studies. 
Direct comparisons with our findings are therefore not possible. In contrast with our review 
(Figure 3), Henrotin 2010 judged Belcaro 2008b, Cisár 2008 and Farid 2007 to be of good to 
very good quality using a different instrument to ours. The criteria for this instrument, as 
described by Henrotin 2010, are presented in Table 16 (number 7). 
 
We assessed the methodological quality of the abovementioned systematic reviews with the 
validated AMSTAR tool (Shea 2007) and present our findings in Table 16. The quality was 
poor, with the exception of Clark 2010.  
 
Authors' conclusions 
 
Implications for practice  
Pycnogenol is marketed to aid in the treatment of the following conditions: ADHD, asthma, 
cholesterol/dyslipidaemia, CVI, diabetes, dysmenorrhoea, endometriosis, erectile 
dysfunction, hypertension, melasma, muscle cramps, osteoarthritis, peri-menopause, 
platelet function and retinopathy (American Botanical Council 2010). Our review shows that 
currently available evidence is not sufficient to support or cordone the use of Pycnogenol for 
the treatment of chronic conditions. Concern about long-term safety of antioxidant 
supplements exists (Bjelakovic 2007; Bjelakovic 2008a; Bjelakovic 2008b); the available 
evidence provides no assurance of the safety of Pycnogenol. 
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Implications for research  
Well-designed, adequately powered randomised controlled trials of Pycnogenol are needed. 
Careful attention should be given to the outcomes to be assessed in future trials to ensure 
that selected outcomes are important to patients and are measured in a standardised 
manner. 
 
Contributions of authors  
AS developed the idea. AS wrote the protocol and review under the guidance of JV. AS and 
JV extracted all the data; AM extracted the results for all relevant outcomes. AM and AS 
summarised and analysed the results, with input from JV. JVi provided input at all stages 
and revised the protocol and review. 
 
Declarations of interest  
None known. 
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Characteristics of studies 
 
Characteristics of included studies  
Arcangeli 2000  
Methods RCT; parallel group design. 
Ethics approval by the "Ministry of Health". 
Treatment duration: two months after a two week run in period. During the run in period neither drugs acting on the 
cardiovascular system nor diuretics, analgesics or anti-inflammatory compounds were allowed. 
No follow-up after end of treatment. 
Participants Total participants: 40 (20 in each group). 
Country and setting: Italy; clinical centre. 
Inclusion criteria: adults with chronic venous insufficiency (CVI) as a result of deep vein thrombosis or idiopathic venous 
lymphatic deficiency. Diagnosis was based on clinical judgement. 
Exclusion criteria: not reported. 
Baseline characteristics: Treatment group: 25% males; age range 34 to 74 years, mean age 57.95 (SD 12.78) years. 
Control group: 40% males; age range 30 to 70 years, mean age 61.40 (SD 10.62) years. 
Concomitant medication: participants were not allowed to take drugs which act upon the cardiovascular system, 
diuretics, or analgesic and anti-inflammatory combinations during the treatment period. 
Diet: a standard diet determined according to participants' energy requirements had to be followed. 
Interventions Treatment: Pycnogenol; 100 mg three times per day for two months. 
Control: "visually matched" placebo; three times per day for two months. 
Route of administration: not reported; assumed to be oral. 
Outcomes 
 Symptom scores (heaviness; swelling; pain of legs): collected at baseline, after 30 days and after 60 days of 
treatment; assessed by a clinical symptomatology score system where 0 = absent, 1 = light, 2 = moderate and 3 = 
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severe; the percentage of participants who had disappearance of each symptom was also calculated. 
 Venous blood flow: collected at baseline, after 30 and after 60 days of treatment; measured with a hand-held Doppler 
ultrasound. 
 Clinical assessment of efficacy: collected at 60 days after treatment; assessed by a semi-qualitative scale where 1 = 
poor, 2 = moderate, 3 = good and 4 = very good. 
 Clinical tolerability: participants were asked to report "adverse effects" anytime during treatment. 
 Biochemical tolerability: blood samples were collected at baseline and after 60 days of treatment for blood tests 
(haematology, blood chemistry, liver functions, renal function); the unit of measurement for each blood test is specified 
in the article. 
Notes Funding source: not reported. 
Study date: 1989. 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear 
"...patients were randomly divided". However, the randomisation method is not reported. 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind". Although it is reported that the placebo "visually matched" 
the test drug, it is not clear whether the placebo was also matched in terms of other characteristics such as 
weight and taste. Pycnogenol is known to have a bitter, astringent taste. 
Incomplete outcome 
data addressed? 
Unclear Not reported whether all randomised participants completed the study, i.e. whether data from all 
participants for all outcomes were collected. 
Free of selective No Protocol not available; pre-specified outcomes not stated in the Methods section. 
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reporting? 
Free of other bias? Unclear Funding source not reported. 
 
Belcaro 2006a  
Methods RCT; parallel group design. 
Treatment duration: six weeks. 
No follow-up after end of treatment. 
Participants Total participants: 30 (divided into three treatment- and one control group). 
Country and setting: not reported, assumed to be Italy; setting not reported. 
Inclusion criteria: insulin-dependent diabetics with foot ulcers appearing for the first time and had been present for at 
least two months; severe diabetic microangiopathy based on blood flow in tibial arteries exceeding 60 mm Hg as 
measured by Laser Doppler skin perfusion pressure. 
Exclusion criteria: severe stenosis or obstruction at the femoral or iliac artery level or recent venous thrombosis as 
indicated by colour duplex imaging; any clinical disease requiring treatment; severe bone or joint problems or limited 
mobility; uncontrolled diabetes; severe hypertension; signs of systemic infections; obesity; recent thrombosis (less than 
six months); and the presence of aneurysms or thrombi. 
Baseline characteristics 
Treatment groups: Pycnogenol oral and local treatment: 37.5% males; assumed mean age 54.3 (SD 4.4) years; 
assumed mean duration of disorder 11.3 (SD 2.6) years. 
Pycnogenol local treatment: 37.5% males; assumed mean age 55.0 (SD 5.0) years; assumed mean duration of disorder 
11.0 (SD 2.4) years. 
Pycnogenol oral treatment: 66.7% males; assumed mean age 55.0 (SD 3.0) years; assumed mean duration of disorder 
11.2 (SD 4.0) years. 
Control group: 50% males; assumed mean age 52.4 (SD 6.1) years; assumed mean duration of disorder 12.0 (SD 3.0) 
years. 
Concomitant treatment: all participants received general ulcer care daily that included washing and cleaning in water 
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and a mild disinfectant (Citrosil, Italy), drying with soft paper tissue and dressed with nonallergic paper and an elastic-
adhesive bandage (Tensoplast, South Africa). 
Exercise: an exercise plan that included an educational video explaining foot protection for diabetics during exercise 
was given to all participants. Friction-free socks were provided that also kept the medication in place during the study 
period. 
Interventions Treatment 
Pycnogenol oral and local treatment: Pycnogenol; 50 mg capsule three times per day orally for six weeks together with 
100 mg powder from two 50 mg capsules placed on ulcerated area daily for six weeks. 
Pycnogenol local treatment: Pycnogenol; 100 mg powder from two 50 mg capsules placed on ulcerated area daily for 
six weeks. 
Pycnogenol oral treatment: Pycnogenol; 50 mg capsule three times per day orally for six weeks. 
Control: no Pycnogenol or other medication, standard ulcer care only as received by the three active treatment groups; 
for six weeks. 
Outcomes 
 Microcirculation-related symptoms (e.g. pain): collected at baseline and after six weeks of treatment; signs and 
symptoms were measured by means of a clinical scale where 0 = absence of symptoms and 10 = very severe signs or 
symptoms. 
 Area of ulceration: collected at baseline and after six weeks of treatment; the area of ulceration was copied on a 
transparent plastic sheet and the relative integral of the area recorded in a computerized Logitech (Palo, Alto, Calif) 
system; measured in mm2. 
 Percentage complete healing: collected after six weeks of treatment; no further detail reported. 
 Microcirculatory parameters (transcutaneous PO2 and PCO2; skin flux at rest; venoarteriolar response): collected at 
baseline and after six weeks of treatment; transcutaneous PO2 and PCO2 were measured in mm Hg with a combined 
measurement (CombiuSensor Kontron, United Kingdom) after heating the skin to 44°C, the measurements were 
recorded after a period of 20 minutes of stabilization and capillarization of the area, and it was made at one centimetre 
away from the ulcer edge in non-inflamed or infected area where the skin was intact; skin flux at rest was measured by 
a Laser Doppler in LDF (laser Doppler flux) units; venoarteriolar response was also measured by a Laser Doppler. 
Because of high cost these parameters were only measured in the group receiving both the oral and local Pycnogenol 
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treatment, the group receiving only the oral Pycnogenol as well as the control group. 
 "Side effects": reported during the six week intervention period; measured by direct questioning about tolerability and 
compliance - particularly gastrointestinal problems, systemic and local skin alterations, signs of allergic reaction and 
any other manifestation. 
Notes Funding source: "The study was not sponsored by companies producing materials and products quoted in the article. 
The compound was supplied, without conditions, by Horphag Research Management SA, Geneva, Switzerland." 
Ethics approval: not reported. 
Percentage complete healing: there could have been more than one ulcer per patient. It is not clear whether all ulcers of 
a patient were completely healed in order to be counted as 'complete healed', or whether one ulcer healed was 
counted. The unit of randomisation was participants, not ulcers.  
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear 
"Patients were randomly assigned to four groups." However, the randomisation method is not reported. 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? No The control group received no treatment (also no placebo) while the three treatment groups got capsules 
for oral or local (or both) use. 
Incomplete outcome 
data addressed? 
Yes No participants were lost to follow-up. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
Free of other bias? Unclear The study was funded by Horphag Research Ltd. This company is the manufacturer and holder of 
Pycnogenol's registered trademark. 
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Belcaro 2008b  
Methods RCT; parallel group design. 
Ethics approval by the ethical committee of the University of Pescara. 
Treatment duration: three months. 
No follow-up after end of treatment. 
Participants Total participants: 156 (77 in the treatment- and 79 in the control group). 
Country and setting: Italy; community setting (Cesarone 2002). 
Inclusion criteria: people with grade I or II osteoarthritis of one or both knees (classified by the American Rheumatism 
Association system), confirmed by x-ray performed by a qualified orthopaedist (Belcaro 2008a); WOMAC (Western 
Ontario and McMaster Universities) pain subscale index of at least 10 out of 20 (Belcaro 2008a); intermittent or constant 
pain in the target knee for at least 50% of the time during the last three months which required medical treatment with 
selective cyclooxygenase-2 (COX-2) inhibitors or other nonsteroidal anti-inflammatory drugs (NSAIDs) (Belcaro 2008a); 
able to perform the treadmill test; understand all questions from the WOMAC questionnaire. 
Exclusion criteria: secondary osteoarthritis due to a known disorder (Belcaro 2008a); joint injection of the target knee 
within the last six months (Belcaro 2008a); cardiovascular disease requiring drug treatment; diabetes; overweight; 
severe metabolic disorders; surgery or arthroscopy three months before inclusion; radiotherapy or chemotherapy; 
pregnant, breastfeeding or planned conception. 
Baseline characteristics: Treatment group: 50.6% males; mean age 48.6 (SD 8.0) years; mean global WOMAC score 
79.2; mean of treadmill test 68 meters; distance (range) achieved with treadmill test 0 to 133 meters. Control group: 
49.4% males; mean age 47.8 (SD 7.7) years; mean global WOMAC score 76.9; mean of treadmill test 65 meters; 
distance (range) achieved with treadmill test 12 to 98 meters. 
Concomitant medication: associated treatments prescribed by the participant's general practitioner were to be reported 
in a diary. 
Interventions Treatment: Pycnogenol; 50 mg capsule two times per day (after breakfast and dinner) for three months. 
Control: placebo that matched the test drug by appearance, size and shape; two capsules daily (after breakfast and 
dinner) for three months. 
Route of administration: orally. 
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Outcomes 
 Symptom scores [pain; stiffness; physical function; global score (sum of previous three scores); negative alterations in 
social functions; sum of emotional parameters]: collected at baseline and after three months of treatment; measured 
by the WOMAC index. The interpretation of the WOMAC scores: total score ranges from 0 (no symptoms) to 96; pain 
score ranges from 0 (no symptoms) to 20; stiffness score ranges from 0 (no symptoms) to 8; and physical function 
score ranges from 0 (no symptoms) to 68. 
 Use of concomitant medication: participants kept a diary of medication prescribed by their general practitioner during 
the treatment period; expressed in percentage reduction at the end of the three months treatment period. 
 Physical performance: collected at baseline and after three months of treatment; measured as the total distance in 
meters on the treadmill that could be covered at 3 km/hour or 8 km/h (inconsistently reported) with an inclination of 
10% without pain. 
 Vascular problems (clinical assessment of ankle and foot edema; ankle and foot edema measured by foot volumetry 
on randomly selected subsample): data for the clinical assessment was collected at baseline and after three months of 
treatment, whereas data on ankle and foot edema measured by foot volumetry was only collected after three months 
of treatment; edema was scored by the investigator as 0 = not visible, 1 = only visible after standing for a "long" time 
or in the evening, 2 = visible during the day but resolves overnight, 3 = visible during the day but only partially resolves 
overnight, 4 = present all the time; the actual foot volume at inclusion was defined as 100%. 
 Reduction in health care costs (drugs and treatments besides NSAIDs; average management; hospital admissions; 
days hospitalised; indirect costs): information was recorded in a specific costing file during the treatment period; 
expressed in percentage reduction at the end of the three months treatment period. 
 "Unwanted effects": reported by participants in diaries during the treatment period. 
Notes Funding source: not reported. However, in another article (Belcaro 2008a) in which a subset of the participants used for 
this study was evaluated for change in certain biochemical parameters, it is reported that the study was supported by 
Horphag Research Ltd. 
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Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Yes Computer generated blocked randomisation. 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind". Although it is reported that the placebo was identical to the 
test drug in terms of appearance, it is not clear whether the placebo was also identical in terms of other 
characteristics such as weight and taste. The test drug is known to have a bitter, astringent taste. 
Incomplete outcome 
data addressed? 
Unclear It is not clear what number of participants was included in the analysis or whether participants were 
analysed according to the group to which they were randomised. 6/77 participants were lost to follow-up 
from the treatment group and 5/79 from the control group. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
Free of other bias? Unclear Funding source not reported in Belcaro 2008b, but another linked study (Belcaro 2008a) suggests that 
Horphag Research was a sponsor. This company is the manufacturer and holder of Pycnogenol's 
registered trademark. 
 
Cisár 2008  
Methods RCT; parallel group design. 
Ethics approval by the Local Ethical Committee of the University Hospital in Bratislava, Slovakia. 
Treatment duration: 12 weeks. 
Follow-up: assumed to be two weeks after end of treatment, at week 14. 
Participants Total participants: 100 (50 in each group). 
Country and setting: Slovakia; outpatients attending the Orthopaedics Department of the University Hospital Ružinov in 
Bratislava. 
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Inclusion criteria: adults (> 25 years) with stage I or II osteoarthritis according to Kellgren-Lawrence in standard AP X-
ray view in at least one target knee; mild to moderate pain in the target knee for at least three months preceding the 
study, and/or morning knee stiffness and/or knee crepitus; females must confirm that they are not presently pregnant 
and do not plan to get pregnant for at least one year after the end of the trial; postmenopausal women must have been 
amenorrhoeic for at least one year. 
Exclusion criteria: participation in another study less than 30 days before the start of the study; moderate or severe 
osteoarthritis (Kellgren-Lawrence stage III or IV); rheumatoid arthritis or other chronic inflammatory disease affecting the 
target joint; secondary osteoarthritis; arthroscopic surgery or other major surgery of the target knee; major trauma of the 
target knee; intra articular injection of corticosteroids or symptomatic slow acting drugs of osteoarthritis (SYSADOA) in 
target knee in the past three months prior to the study; acute infection of the target knee in the last six months, or if the 
participants started any form of physiotherapy in the three weeks prior to the study; having a significant psychiatric 
disorder (including depression) or receiving antipsychotic medication; breastfeeding. 
Baseline characteristics: Treatment group: 28% males; "average" age 54 (range 25 to 65) years; "average" body mass 
index (BMI) 27.3 (range 16.9 to 35.4) kg/m2. Control group: 36% males; "average" age 54 (range 30 to 65) years; 
"average" BMI 27.2 (range 20.7 to 37.2) kg/m2. 
Concomitant medication: participants could use NSAIDs or other analgesics prescribed prior to the start of the study 
and could change the dose and frequency of drug intake, but they had to report changes at each visit. 
Interventions Treatment: Pycnogenol; 50 mg pills three times per day with meals for 12 weeks. 
Control: placebo that matched the test drug in terms of appearance; three pills per day with meals for 12 weeks. 
Route of administration: orally. 
Outcomes 
 Symptom scores (pain; stiffness; ability to perform daily activity; total WOMAC score): collected at baseline and then 
every two weeks of treatment until the end of the study at week 14; measured by the WOMAC questionnaire (in 
Slovakian language) that rates pain, stiffness and ability to perform daily activity on a five-point Likert scale. 
 Measuring pain with a visual analogue scale (VAS): "filled in by the patients each week during the whole study (14 
weeks)"; intensity of pain is rated on a visual analogue scale where 0 = no pain and 100 = very severe pain. 
 Change in analgesic use: collected at baseline and then "at each visit" (assumed to be every four weeks); reported in 
percentage reduction or increase. 
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 "Adverse effects": "Patients were asked every 2 weeks to report any unwanted or unusual effects". 
 Safety by means of basic biochemical parameters (glucose; uric acid; total cholesterol; HDL-cholesterol; LDL-
cholesterol; triacylglycerol; high sensitivity C-reactive protein; gamma-glutamyl transferase; alkaline phosphatase; 
aspartate aminotransferase; alanine aminotransferase): collected at baseline, after three months of treatment and at 
the end of the study (week 14); fasting venous blood were drawn in the mornings and the serum were analysed by 
"standard biochemical procedures using the Hitachi 911 automatic analyser and kits, Roche, Switzerland". 
Notes Funding source: : "This study was supported by Horphag Research Ltd, partly by VEGA Grant No. 1/2294/05, 
1/1157/04 and 1/3037/06 of Ministry of Education of Slovakia and Mind and Health, civil association." 
Duration of the trial: not clear from the article. "Patients were investigated at the start, at 3 months and 4 weeks after 
finishing treatment." From this quote it looks as if the treatment was given for three months (12 weeks) after which there 
was a four week wash-out period before the final follow-up data collection was performed (in other words a total study 
duration of 16 weeks). However, the results are reported, inter alia, at weeks 12 and 14 as well as at week 15. This 
does not correspond with the above quote. 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear 
"The subjects were randomly allocated..." However, the randomisation method is not reported. 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind" and that the placebo was identical to the test drug in terms 
of appearance. However, it is not reported whether the placebo was also identical in terms of other 
characteristics such as weight and taste. The test drug is known to have a bitter, astringent taste. 
Incomplete outcome 
data addressed? 
No "Data of all patients were evaluated in the intention-to-treat analysis." However, it is not described what the 
primary study authors mean with the term "intention-to-treat analysis" and how they handled the missing 
data from participants who were lost to follow-up. 6/50 participants were lost to follow-up from the 
treatment group and 13/50 from the control group - big difference. 
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Free of selective 
reporting? 
Unclear Protocol not available. 
Free of other bias? Unclear The study was, amongst others, funded by Horphag Research Ltd. This company is the manufacturer and 
holder of Pycnogenol's registered trademark. 
 
Duracková 2003  
Methods RCT; parallel group design. 
Ethics approval by the Ethical Committee of the Comenius University Hospital, Slovak Republic. 
Treatment duration: three months. 
Follow-up: one month after end of treatment, at the end of month four. 
Participants Total participants: 21 (13 in the treatment- and 8 in the control group). 
Country and setting: not reported, assumed to be Slovak Republic; setting not reported. 
Inclusion criteria: men with erectile dysfunction (ED) as determined by means of the International Index of Erectile 
Function (IIEF-5) which consists of a questionnaire of five questions where 25 points is the maximum score. 
Exclusion criteria: acute inflammatory cardiovascular disease; renal failure; hepatic insufficiency; endocrine 
abnormalities (testosterone deficit); psychiatric disorders; no concomitant use of other therapies for ED. 
Baseline characteristics: Treatment group: 100% males; "average" ED score (as measured by IIEF-5) 12.6 (unspecified 
measure of variation 1.1). Control group: 100% males; "average" ED score (as measured by IIEF-5) 11.3 (unspecified 
measure of variation 1.3). No further detail per group is reported. Overall age (n=21): "average" age 46.5 (unspecified 
measure of variation 12.5) years, range 22 to 69 years. 
Concomitant medication: none permitted (also no vitamin C and E supplements). 
Interventions Treatment: Pycnogenol; two 20 mg pills three times per day (total of 120 mg/day) for three months. 
Control: placebo; two pills three times per day for three months. 
Route of administration: orally. 
Outcomes 
 Symptom scores: collected at baseline, and at the end of the first, second and third month of treatment, as well as at 
the end of month four (one month after end of treatment); assessed using IIEF-5 questionnaire where normal function 
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= 21 to 25 points, mild ED = 16 to 20 points, moderate ED = 11 to 15 points and severe ED = "less than 10 points". 
 Total cholesterol levels: collected at baseline, at the end of the first and third month as well as at the end of month four 
(one month after end of treatment); analysed by standard biochemical procedures using a Hitachi 911 automatic 
analyser (Roche, Switzerland); measured in mmol/l. 
 LDL-cholesterol levels: collected at baseline, at the end of the first and third month as well as at the end of month four 
(one month after end of treatment); analysed by standard biochemical procedures using a Hitachi 911 automatic 
analyser (Roche, Switzerland); measured in mmol/l. 
 HDL-cholesterol levels: collected at baseline, at the end of the first and third month as well as at the end of month four 
(one month after end of treatment); analysed by standard biochemical procedures using a Hitachi 911 automatic 
analyser (Roche, Switzerland); measured in mmol/l. 
 LDL/HDL ratio: collected at baseline, at the end of the first and third month as well as at the end of month four (one 
month after end of treatment). 
 Triacylglycerol (TAG) levels: no detail reported. 
 Antioxidant activity in the blood: collected at baseline, at the end of the first and third month as well as at the end of 
month four (one month after end of treatment); determined by the ferric reducing ability of plasma (FRAP) method; 
measured in mmol of trolox/l; reported in percentage where 100% is the antioxidative activity of plasma before the 
trial. 
Notes Funding source: "This study was supported partly by VEGA grants No. 1/8303/01, 1/9243/02 of Ministry of Education of 
the Slovak Republic and by Drug Research Institute, Modra, Slovak Republic." 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear 
"Selection to the different groups was randomised." However, the randomisation method is not reported. 
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Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind". However, it is not reported whether the placebo was 
identical to the test drug in all important aspects (i.e. matched in terms of shape, size, colour, taste, and 
weight). 
Incomplete outcome 
data addressed? 
Yes No participants were lost to follow-up. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
Free of other bias? Unclear Incomplete baseline characteristics, i.e. unclear whether the participants of the treatment and control 
groups were similar with respect to various important baseline characteristics. 
 
Farid 2007  
Methods RCT; parallel group design. 
Ethics approval by the ethical committee of Mashhad Medical University. 
Treatment duration: three months. 
No follow-up after end of treatment. 
Participants Total participants: 37 (19 in the treatment- and 18 in the control group). 
Country and setting: Iran; Rheumatology Department of Mashhad Medical University. 
Inclusion criteria: adults (25 to 65 years old) with primary osteoarthritis in the knee (according to the American College 
Rheumatology criteria grade I or II); WOMAC pain subscale index of at least 40 at baseline; intermittent or constant pain 
in the target knee for at least 50% of the time in the last three months that required medical treatment in the form of 
COX-2 inhibitors or other NSAIDs on most days. 
Exclusion criteria: secondary osteoarthritis; arthroscopy, surgery, or a joint injection of the target knee within the 
previous six months; prior history of knee joint replacement; any serious systemic disease; any other chronic 
inflammatory disease; use of any supplement apart from a multivitamin daily. 
Baseline characteristics: Treatment group: 11.1% males; mean age 47.5 (SD 7.4) years; mean BMI 22.7 (SD 3.2) 
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kg/m2; mean duration of disorder symptoms 3.8 (SD 5.1) years; 38.9% participants had knee osteoarthritis grade I; 
mean NSAIDs or COX-2 inhibitors use 15.6 (SD 4.3) days per month; mean pain WOMAC score 292 (SD 101); mean 
stiffness WOMAC score 110 (SD 66); mean physical function WOMAC score 997 (SD 352); mean composite WOMAC 
score 1400 (SD 482). Control group: 5.9% males; mean age 48.9 (SD 9.6) years; mean BMI 23.5 (SD 2.8) kg/m2; mean 
duration of disorder symptoms 4.5 (SD 4.7) years; 41.2% participants had knee osteoarthritis grade I; mean NSAIDs or 
COX-2 inhibitors use 14.8 (SD 5.6) days per month; mean pain WOMAC score 301 (SD 119); mean stiffness WOMAC 
score 120 (SD 63); mean physical function WOMAC score 1042 (SD 420); mean composite WOMAC score 1463 (SD 
552). 
Concomitant medication: COX-2 and other NSAIDs as medical treatment for pain in the target knee. 
Interventions Treatment: Pycnogenol; 50 mg pills three times per day for three months. 
Control: placebo that matched the test drug in terms of appearance; three times per day for three months. 
Route of administration: orally. 
Outcomes 
 Symptom scores (pain; stiffness; physical function; composite WOMAC score): collected at baseline and then after 30, 
60 and 90 days of treatment; measured by the WOMAC index which consists out of a total of 24 visual analogue 
scales. 
 Use of concomitant medication (NSAIDs and COX-2): collected after 30, 60 and 90 days of treatment; participants 
were asked to keep a diary of medication usage (frequency and dose); data are reported as change in the number of 
pills per patient per month. 
 Participants' treatment compliance: collected after 30, 60, and 90 days of treatment; measured by means of pill 
counting. 
 Clinical adverse events: collected after 30, 60 and 90 days of treatment; volunteered reporting by participants or data 
are extracted by questioning. 
 Safety by means of biochemical parameters (fasting blood glucose; alanine aminotransferase; aspartate 
aminotransferase; urea; creatinine; complete blood count; haemoglobin levels; hematocrit levels): collected at baseline 
and after 90 days of treatment; assessed by the clinical laboratory of Mashhad Medical School. 
Notes Funding source: "This research was supported by Horphag Research, Inc which also provided the supplement and 
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placebo pills." 
Title: the claim made about stiffness in the title of this study is not reflected in the results. 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear 
"...patients...were allocated randomly to either..." However, the randomisation method is not reported. 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind" and that the placebo was identical to the test drug in terms 
of appearance. However, it is not reported whether the placebo was also identical in terms of other 
characteristics such as weight and taste. The test drug is known to have a bitter, astringent taste. 
Incomplete outcome 
data addressed? 
Unclear "Analysis was performed according to the intention-to-treat principle." However, it is not described what the 
primary study authors mean with the term "intention-to-treat analysis" and how they handled the missing 
data from participants who were lost to follow-up. 1/19 participants were lost to follow-up from the 
treatment group and 1/18 from the control group. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
Free of other bias? Unclear The study was funded by Horphag Research Ltd. This company is the manufacturer and holder of 
Pycnogenol's registered trademark. 
 
Hosseini 2001a  
Methods RCT; crossover design. 
Ethics approval by the Human Subjects Committee of Mashhad University of Medical Sciences, Mashhad, Iran. 
Treatment duration: four weeks per arm. 
No follow-up after end of treatment. 
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Participants Total participants: 26 enrolled; 22 completed the first period and 19 completed the second period. 
Country and setting: Iran; Allergy Clinic of Mashhad University of Medical Sciences. 
Inclusion criteria: adults (18 to 60 years old) with asthma according to the American Thoraic Society criteria; baseline 
forced expiratory volume in one second (FEV1) should be 30 to 75% of predicted normal value, with an increase in FEV1 
of > 15% of pretreatment value after two puffs of a beta-adrenergic agonist. 
Exclusion criteria: having emphysema, bronchitis, renal, hepatic, cardiac, or endocrine disease; pregnant women and 
women of childbearing potential; NSAIDs use (including aspirin); vitamin supplement use; unwilling to exclude wine 
from their diet during the study period. 
Baseline characteristics: 45.5% males (10/22); mean age 32 (range 18 to 50) years; mean duration of disorder 8 (range 
1 to 16) years. 
Concomitant medication: usual medications could be used except for glucocorticoids, leukotriene antagonists, 
multivitamins, aspirin and any other NSAIDs. 
Interventions Treatment: Pycnogenol; 1 mg/lb/day (maximum 200 mg/day) for four weeks. 
Control: placebo pills for four weeks. 
Wash-out period: none. 
Route of administration: orally. 
Outcomes 
 Symptom scores: collected at baseline, at the end of the fourth week (after treatment with either the test drug or 
placebo) and at the end of the eighth week (after four weeks on the remaining treatment option); measured by means 
of a symptom severity scale where 1 = mild intermittent, 2 = mild persistent, 3 = moderate persistent, and 4 = severe 
persistent. 
 Pulmonary functions [% predicted FEV1; FEV1/forced vital capacity (FVC)]: collected at baseline, at the end of the 
fourth week (after treatment with either the test drug or placebo) and at the end of the eighth week (after four weeks 
on the remaining treatment option); measured by means of spirometry 
 Cysteinyl-leukotrienes C4, D4, and E4 levels: collected at baseline, at the end of the fourth week (after treatment with 
either the test drug or placebo) and at the end of the eighth week (after four weeks on the remaining treatment option); 
assayed in triplicate with the use of a Cayman Chemical Cysteinyl-Leukotriene Enzyme Immunoassay Kit (Ann Arbor, 
MI); expressed in pg/ml. 
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 "Adverse experiences": all symptoms that were not observed to be present at baseline were recorded as "adverse 
experiences"; it is not reported whether the participants or investigators or both recorded the symptoms. 
Notes Funding source: the test drug and placebo was a "kind gift" of Cognis Corporation (Kankakee, IL). The study was also 
funded by Arizona Foundation and other unspecified grants. 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear "Subjects were randomly assigned to receive Pycnogenol...or placebo pills..." However, the randomisation 
method is not reported. 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind". However, it is not reported whether the placebo was 
identical to the test drug in all important aspects (i.e. matched in terms of shape, size, colour, taste, and 
weight). 
Incomplete outcome 
data addressed? 
Unclear It is not clear what number of participants was included in the analysis. In total, 7/26 participants were lost 
to follow-up of which four were from the first period and three from the second period. Furthermore, it is not 
reported whether the analysis was based on the first period data only, or both. 
Free of selective 
reporting? 
Unclear Protocol not available.  
Free of other bias? Yes Trial was not sponsored by the manufacturer of Pycnogenol. 
 
Hosseini 2001b  
Methods RCT; crossover design. 
Ethics approval by the Institutional Review Board of the University of Arizona, United States of America (USA). 
Treatment duration: eight weeks per arm, after a one week run in period. During the run in period all participants took 
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placebo pills. 
No follow-up after end of treatment. 
Participants Total participants: 11. 
Country and setting: not reported, assumed to be the USA; setting not reported. 
Inclusion criteria: non-smoking people with mild hypertension (stage I) who complied fully to take the provided placebo 
pills during the run in period; blood pressure measured three times in sitting patients after a fifteen minute rest should 
give a systolic blood pressure of between 140 and 159 mm Hg, and/or diastolic blood pressure between 90 and 99 mm 
Hg. 
Exclusion criteria: taking antihypertensive medication; taking NSAIDs, including aspirin; use of tobacco; taking any 
vitamin supplements other than one multivitamin tablet daily. 
Baseline characteristics: 63.6% males; mean age 50.3 (SD 9.3) years. 
Concomitant medication: permitted, but not specified. 
Diet: participants were asked to exclude wine from their diets for the duration of the study. 
Interventions Treatment: Pycnogenol; four 50 mg pills per day (encouraged to be taken in the morning); for eight weeks. 
Control: four placebo pills per day (encouraged to be taken in the morning); for eight weeks. 
Wash-out period: none. The following reason was reported: "...we have previously shown that Pycnogenol's effects on 
platelet aggregation in smokers disappeared three days after the cessation of its use." 
Route of administration: orally. 
Outcomes 
 Concomitant medication use: not reported when collected, assumed to be only after the 16 week study period; data 
obtained by questioning participants. 
 Blood pressure (systolic and diastolic): collected at baseline (data from run in period and week 0 combined), and then 
at the end of week seven and eight as well as at the end of week 15 and 16; the results of week seven and eight as 
well as of week 15 and 16 were combined to produce the final result after each period; measured in triplicate in a 
sitting position after a fifteen minute rest; measured in mm Hg. 
 Participants' treatment compliance: collected after the one week run in period as well as after week eight and week 16; 
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measured by means of pill counting. 
 Thromboxane B2 levels: collected at baseline and then at the end of week seven and eight as well as at the end of 
week 15 and 16; the results of week seven and eight as well as of week 15 and 16 were combined to produce the final 
result after each period; assayed in triplicate by Neogen Corportaion (Lexington, KY) thromboxane B2 enzyme-linked 
immuno-absorbent assay (ELISA) kit; measured in ng/ml. 
 Adverse events: not reported when collected, assumed to be after each eight weeks arm; data collected by 
questioning participants. 
 Safety by means of blood tests: collected at baseline and then at the end of week seven and (assumed) eight as well 
as at the end of week 15 and 16; the results of week seven and eight as well as of week 15 and 16 were combined to 
produce the final result after each period; no further detail was provided. 
Notes Funding source: "The Pycnogenol pills and placebo were obtained from the Cognis Corporation (LaGrange, Illinois)." 
The study was "supported by a grant from Horphag, Inc". 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Yes 
"...randomized using a statistical formula prepared by the Biostatistics department..." 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind". However, it is not reported whether the placebo was 
identical to the test drug in all important aspects (i.e. matched in terms of shape, size, colour, taste, and 
weight). 
Incomplete outcome 
data addressed? 
Yes No participants were lost to follow-up. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
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Free of other bias? Unclear The study was funded by Horphag Research Ltd. This company is the manufacturer and holder of 
Pycnogenol's registered trademark. 
 
Lau 2004  
Methods RCT; parallel group design. 
Ethics approval by the Loma Linda University Institutional Review Board for Human Studies, California, USA. 
Treatment duration: three months after a one week run in period. It is not reported what the purpose of the run in period 
was. 
No follow-up after end of treatment. 
Participants Total participants: 60 (30 in each group). 
Country and setting: USA; recruited from the Pediatric Teaching Office of Loma Linda University Children's Hospital 
(California) and from local physicians' clinics. 
Inclusion criteria: children (6 to 18 years old) with mild to moderate asthma as defined by the American Thoracic Society 
criteria; 50 - 85% of predicted normal FEV1 and increase of 12% or more after two puffs of rescue inhaler; a severe 
asthma attack or lower respiratory tract infection in one month before the start of the trial. 
Exclusion criteria: unable to co-operate with pulmonary function and/or laboratory tests; unable to follow instructions; 
unable to swallow pills; taking steriodal- or nonsteroidal anti-inflammatory drugs. 
Baseline characteristics: Treatment group: 57% males; mean age 14 (range 6 to 16) years; % predicted peak expiratory 
flow (PEF) 69.7 [standard error of the mean (SEM) 1.7]; number of participants using rescue inhaler as needed 30; 
number of participants using Accolate 5. Control group: 60% males; mean age 14 (range 7 to 18) years; % predicted 
PEF 69.9 (SEM 1.6); number of participants using rescue inhaler as needed 30; number of participants using oral 
medication (Accolate) 4. 
Concomitant medication: not reported whether specific medication was not permitted; however, change in use of rescue 
inhaler (albuterol) and oral medication Accolate (zafirlukast; leukotriene receptor antagonist) were reported as outcomes 
in the trial, therefore we know that these specifically were permitted. 
Interventions Treatment: Pycnogenol; 1 mg/lb body weight in two divided dosages daily for three months. 
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Control: placebo "indistinguishable" from the test drug; two times per day for three months. 
Route of administration: orally. 
Outcomes 
 PEF rate: collected at baseline and then at the end of the first, second and third month of treatment; measured with an 
Assess Peak Flow Meter (Respironics, Cedar Grove, New Jersey); participants were asked to take three PEF rate 
readings every evening and record the best one on a diary card which was collected by an investigator at the end of 
each month of treatment; values are expressed in percentage predicted values. 
 Symptom scores: collected at baseline and then at the end of the first, second and third month of treatment; 
participants reported their scores every evening on diary cards which was collected by an investigator at the end of 
each month of treatment; measured on a scale from 0 to 4 where 0 = no symptoms, 1 = mild symptoms - not 
disturbing, 2 = moderate symptoms - somewhat disturbing, 3 = severe symptoms - interfered with daily activities, 4 = 
very severe symptoms - could not go anywhere. Results were also expressed in the number of participants with a 
decrease in symptom scores. 
 Use of oral medication (Accolate): collected at baseline and then at the end of the first, second and third month of 
treatment; recorded by participants every evening in their diary cards and collected by an investigator at the end of 
each month of treatment; measured as number of participants using oral medication. 
 Use of rescue inhaler (albuterol): collected at baseline and then at the end of the first, second and third month of 
treatment; recorded by participants every evening in their diary cards and collected by an investigator at the end of 
each month of treatment; recorded as the number of puffs per 24 hours as well as the number of participants off the 
rescue inhaler. 
 Participants' treatment compliance: collected at the end of the first, second and third month of treatment; the bottles of 
capsules were collected and the capsules counted to ascertain compliance; reported in terms of percentage 
compliance. 
 Urinary leukotriene C4/D4/E4 levels: collected at baseline and then at the end of the first, second and third month of 
treatment; assayed in duplicate by an enzyme immunoassay system (Biotrak, Amersham Pharmacia Biotech, United 
Kindgom); unit of measurement is pg/ml. 
 "Adverse side effects": not reported when it was collected, assumed to be during the three months treatment period 
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via their diary cards; reported by participants. 
Notes Funding source: "This study was supported by the Chan Shun International Foundation, San Francisco, CA, and 
Horphag Research, Geneva, Switzerland. Neither of the sponsors is the manufacturer of the Pycnogenol capsules used 
in this study."  
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear 
"Sixty patients were randomized so that..." However, the randomisation method is not reported. 
Allocation 
concealment? 
Unclear The treatment was "identified by preassigned codes prepared by an independent laboratory that was not 
involved in conducting the experiment". It is not clear whether the coding was sufficient to protect 
sequence generation and whether this above quote refers to blinding rather than to allocation 
concealment. 
Blinding? Yes It is reported that the study was "double-blind". This is confirmed by the following quotes: 
"Neither the subjects nor the persons who evaluated the symptoms had knowledge of the identity of the 
supplement." 
"...placebo capsules indistinguishable from Pycnogenol...". 
Incomplete outcome 
data addressed? 
Unclear Not reported whether all randomised participants completed the study, i.e. whether data from all 
participants for all outcomes were collected.  
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
Free of other bias? Unclear The study was, amongst others, funded by Horphag Research Ltd. This company is the manufacturer and 
holder of Pycnogenol's registered trademark. 
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Liu 2004a  
Methods RCT; parallel group design. 
Treatment duration: 12 weeks. 
No follow-up after end of treatment. 
Participants Total participants: 77 (34 in the treatment- and 43 in the control group). 
Country and setting: China (Beijing and ShanDong); recruited from three hospital outpatient departments. 
Inclusion criteria: diabetes mellitus type II according to the WHO 1999 diagnostic criteria for diabetes. 
Exclusion criteria: pregnant or breastfeeding; use of vitamin supplements during the study period. 
Baseline characteristics: Treatment group: 52.9% males; median age 54 (interquartile range 45 to 62) years; median 
weight 69 (interquartile range 64 to 77) kg; median height 168 (interquartile range 162 to 172) cm. Control group: 60.5% 
males; median age 58 (interquartile range 47 to 66) years; median weight 68 (interquartile range 62 to 75) kg; median 
height 165 (interquartile range 162 to 171) cm. 
Concomitant medication: conventional oral antidiabetic medication as needed was permitted. 
Interventions Treatment: Pycnogenol; 100 mg for 12 weeks. 
Control: placebo; for 12 weeks. 
Route of administration: not reported, assumed to be oral. 
Outcomes 
 Blood glucose levels: collected at baseline and then in two week intervals until the end of the 12 week treatment; 
measured enzymatically; measured in mmol/l and reported as percentage decrease relative to pretreatment levels. 
 HbA1c levels: collected at baseline and then at the end of the first, second and third month of treatment; measured by 
high performance liquid chromatography (HPLC) and reported as percentage decrease relative to pretreatment levels. 
 Endothelin-1 levels: collected at baseline and then at the end of the first, second and third month of treatment; 
measured by immuno-assay and reported as percentage decrease relative to pretreatment levels. 
 6-keto-prostaglandin F1a levels: collected at baseline and then at the end of the first, second and third month of 
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treatment; measured by immuno-assay and reported as percentage decrease relative to pretreatment levels. 
 Change in nitrogen monoxide levels: assumed to be collected at baseline and then at the end of the first, second and 
third month of treatment; measured by colorimetric assay for nitrite/nitrate and reported in nmol/l. 
 "Unwanted effects": not reported when it was collected, assumed to be during the 12 week study period; it is not 
reported whether the participants or investigators recorded the symptoms. 
 Safety [vital signs, ECG (electrocardiography), blood urea nitrogen, electrolytes and creatinine concentration]: 
collected at baseline and again at the end of the 12 week treatment period. 
Notes Funding source: not reported. 
Ethics approval: not reported. 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear "The treatment groups were randomized in respect to gender, age and anti-diabetic medication." However, 
the randomisation method is not reported. 
Allocation 
concealment? 
Unclear Not reported.  
Blinding? Unclear It is reported that the study was "double-blind". However, it is not reported whether the placebo was 
identical to the test drug in all important aspects (i.e. matched in terms of shape, size, colour, taste, and 
weight). 
Incomplete outcome 
data addressed? 
Yes No participants were lost to follow-up. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
Free of other bias? Unclear Funding source not reported. 
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Liu 2004c  
Methods RCT; parallel group design. 
Treatment duration: 12 weeks after a two week run in period. During the run in period all participants received placebo 
instead of their usual medication to confirm diagnosis. 
No follow-up after end of treatment. 
Participants Total participants: 58 (28 in the treatment- and 30 in the control group). 
Country and setting: China (Beijing and ShanDong); recruited from three hospital outpatient departments. 
Inclusion criteria: hypertension according to the WHO 1999 diagnostic criteria for diabetes mellitus; complied fully to 
take the provided placebo during the run in period. 
Exclusion criteria: pregnant or breastfeeding; malignant hypertension; use of vitamin supplements during the study 
period. 
Baseline characteristics: Treatment group: 53.6% males; median age 56 (interquartile range 46 to 64) years; median 
weight 69 (interquartile range 64 to 76) kg; median "stature" 168 (interquartile range 162 to 172) cm. Control group: 
60% males; median age 58 (interquartile range 46 to 66) years; median weight 68 (interquartile range 62 to 75) kg; 
median "stature" 164 (interquartile range 160 to 171) cm. 
Concomitant medication: after the two week run in period on placebo, all participants were put on a calcium antagonist 
(nifedipine, sustained release tablets, 5 mg, Shanghai Pharmaceuticals Co, Ltd.) The dose nifedipine was 20 mg 
(frequency not reported, assumed to be daily) initially, and then adjusted at two week intervals (either reduced or 
increased with 5 mg) as needed to sustain "stable blood pressure". 
Interventions Treatment: Pycnogenol; 100 mg; for 12 weeks. 
Control: placebo; for 12 weeks. 
Route of administration: not reported, assumed to be oral. 
Outcomes 
 Nifedipine dose needed to control blood pressure: collected at the end of the 12 week treatment period; measured in 
terms of the number of participants using a specific dose nifedipine (10 mg, 15 mg, or "20 + 30 mg"). This outcome is 
dependent on the blood pressure measurements during the treatment period since the nifedipine dose was adjusted 
every two weeks as needed to sustain "stable blood pressure". Blood pressure was collected at baseline and then at 
two week intervals until the end of the 12 week treatment period; measured at 08:30 a.m., 90 minutes after intake of 
medication, after which they rested for 15 minutes followed by a measurement in the sitting upright position; the mean 
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of the two measurements was recorded. 
 Endothelin-1 levels: collected at baseline and then at the end of the first, second and third month of treatment; 
quantified in plasma by radio-immunoassay (Beijing Huaying Biological Technology Company); reported as 
percentage decrease relative to pretreatment levels. 
 6-keto-prostaglandin F1a levels: collected at baseline and then at the end of the first, second and third month of 
treatment; quantified in plasma by radio-immunoassay (Beijing Huaying Biological Technology Company); reported as 
percentage decrease relative to pretreatment levels. 
 Angiotensin II levels: collected at baseline and then at the end of the first, second and third month of treatment; 
quantified in plasma by radio-immunoassay (Beijing Huaying Biological Technology Company); reported as 
percentage decrease relative to pretreatment levels. 
 Nitrogen monoxide levels: collected at baseline and then at the end of the first, second and third month of treatment; 
analysed using a calorimetric assay for nitrite/nitrate (Nanjing Jiancheng Biological Technology Company); measured 
in nmol/l. 
 "Unwanted effects": not reported when it was collected, assumed to be during the 12 week treatment period; reported 
by participants. 
 Safety by means of determining electrolytes, creatinine, and blood urea nitrogen levels: collected at baseline and 
again at the end of the 12 week treatment period, no further detail reported. 
 Safety by means of measuring heart rate: collected at baseline and then at two week intervals until the end of the 12 
week treatment period; no further detail reported. 
Notes Funding source: not reported. 
Ethics approval: not reported. 
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Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear 
"Patients were randomized to receive either...". However, the randomisation method is not reported. 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind". However, it is not reported whether the placebo was 
identical to the test drug in all important aspects (i.e. matched in terms of shape, size, colour, taste, and 
weight). 
Incomplete outcome 
data addressed? 
Yes No participants were lost to follow-up. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
Free of other bias? Unclear Funding source not reported. 
 
Petrassi 2000  
Methods RCT; parallel group design. 
Treatment duration: two months after a two week run in period. During the run in period participants were not allowed to 
take drugs acting on the cardiovascular system, diuretics, analgesics or anti-inflammatory compounds. 
No follow-up after end of treatment. 
Participants Total participants: 20 (10 in each group). 
Country and setting: not reported, assumed to be Italy; setting not reported. 
Inclusion criteria: participants with symptoms of chronic venous insufficiency (CVI) ("heaviness and subcutaneous 
swelling") and a venous blood pressure higher than 40 mm Hg. 
Exclusion criteria: none reported. 
Baseline characteristics: Treatment group: 20% males; mean age 47.7 (assumed SD 3.65) years. Control group: 10% 
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males; mean age 36.7 (assumed SD 3.66) years. 
Concomitant medication: during the two month treatment period participants were not allowed to take drugs affecting 
the cardiovascular system, diuretics, analgesics or anti-inflammatory compounds. 
Diet: a "standard diet" according to participants' energy needs was prescribed by a dietary service. 
Interventions Treatment: Pycnogenol; 100 mg three times per day for two months. 
Control: placebo indistinguishable from the test drug; three times per day for two months. 
Route of administration: orally. 
Outcomes 
 Symptom scores (feeling of heaviness, swelling and evening edema, localized or diffuse leg pain, night cramps, 
paraesthesiae): collected at baseline and then at the end of the first and second month of treatment; assessed 
clinically using a "4-item scale" where 0 = absent, 1 = light, 2 = moderate, and 3 = severe; the percentage of 
participants showing disappearance of each symptom was also calculated and analysed. 
 Ambulatory venous pressure*: collected at baseline and then at the end of the first and second month of treatment; 
measured on each leg in a standing position after a 30 minute acclimatization period at room temperature (21 to 23 
ºC); measured in mm Hg. 
 Physician's judgement of efficacy and safety of the treatment*: collected at the end of the two month treatment period; 
assessed by a "semi-quantitative 4-point scale" where 1 = poor, 2 = moderate, 3 = good, and 4 = very good. 
 Safety evaluated by means of biochemical tests (haematology, blood chemistry, hepatic functions, renal functions)*: 
collected at baseline and at the end of the two month treatment period; analysed by various laboratory tests; the unit 
of measurement for each blood test is specified in the article. 
 Clinical tolerability*: collected during the trial; not reported whether participants or investigator reported the "side 
effects". 
Notes Ethics approval: not reported. 
Funding source: not reported. 
Study design and results: after the two month treatment 20 additional patients with CVI were added to the study without 
randomisation. They received the same Pycnogenol or placebo (same dose) for the same time period (60 days). 
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Results of many outcomes were pooled so that we could not extract the results from the randomised arm of the trial 
separately. We have reported all the outcomes, but indicated with an asterisk (*) those outcomes of which the results 
were pooled. We did not extract pooled results. 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Yes 
"...according to a computer-elaborated simple randomization table." 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Yes It is reported that the study was "double-blind". Furthermore, "the drugs were prepared in white opaque 
capsules in order to make the lightly pinkish-coloured Pycnogenol indistinct from placebo (lactose)". 
Incomplete outcome 
data addressed? 
Yes For the outcomes of which the results were reported separately for the randomised and non-randomised 
phase of the trial, all participants were included into the analyses. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section; no results were reported 
for the outcomes 'change in night cramps' and 'change in paraesthesiae'. 
Free of other bias? Unclear Funding source not reported. 
 
Steigerwalt 2009  
Methods RCT; parallel group design. 
Treatment duration: two months. 
Follow-up: one month after end of treatment, at the end of month three. 
Participants Total participants: 46 (24 in the treatment- and 22 in the control group). 
Country and setting: not reported, Italy; setting not reported. 
Inclusion criteria: moderate diabetic retinopathy as judged by existence of macular edema and retinal swelling and 
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presence of minor exudates and haemorrhages; diabetes mellitus type II for at least four years; well controlled blood 
glucose levels by diet and oral antidiabetic medication (HbA1c < 7%). 
Exclusion criteria: proliferative retinopathy, severe exudates, progressive haemorrhage and previous haemorrhage; any 
other ophthalmologic condition than diabetic retinopathy, including intraocular hypertension  21 mm Hg; those who had 
previous surgical or laser treatment or other invasive interventions; those with systemic hypertension requiring medical 
treatment. 
Baseline characteristics: Treatment group: 58.3% males; assumed mean age 51.2 (SD 5.4) years; assumed mean 
duration of disorder 6.4 (SD 0.6) years; assumed mean HbA1c levels 6.9 (SD 0.1) %. Control group: 68.2% males; 
assumed mean age 52.3 (SD 6.1) years; assumed mean duration of disorder 6.5 (SD 0.5) years; assumed mean HbA1c 
6.8 (SD 0.2) %. 
Concomitant medication: not reported, but control of blood glucose levels by oral antidiabetic medication was part of the 
inclusion criteria and thus permitted. 
Interventions Treatment: Pycnogenol; three 50 mg tablets per day after breakfast for two months. 
Control: placebo; three tablets per day after breakfast for two months. 
Route of administration: orally. 
Outcomes 
 Visual acuity as perceived by participants: "...subjectively perceived visual improvement..."; no detail reported. 
 Visual acuity as measured by a professional: collected at baseline, after two months of treatment as well as one month 
after end of treatment; measured by means of the standard Snellen chart. 
 Retinal blood flow: collected at baseline, after two months of treatment as well as one month after end of treatment; 
measured quantitatively and noninvasively by colour duplex scanning; expressed in cm/s. 
 Diastolic retinal blood flow relative to maximum systolic flow: collected at baseline, after two months of treatment as 
well as one month after end of treatment; "expressed as flow velocity at the central retinal artery". 
 Retinal edema score: collected at baseline, after two months of treatment as well as one month after end of treatment; 
measured on a scale ranged from 0 to 6 where 0 = no diabetic macular edema, 2 = mild diabetic macular edema, 4 = 
moderate diabetic macular edema, and 6 = severe diabetic macular edema. 
 Retinal thickness: collected at baseline, after two months of treatment as well as one month after end of treatment; 
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measured in m by means of resolution ultrasound at 14 MHz from Esaote (Genoa, Italy); ultrasound was conducted 
twice by two experienced physicians and the average of the two measurements is presented as percentage change 
from baseline set at 100%. 
 "Side effects": not reported how and by whom side effects were monitored. 
Notes Ethics approval: not reported. 
Funding source: not reported. 
Contact author: the contact author is a director of Horphag Research, the manufacturing company of Pycnogenol. 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Yes "Patients were allocated to treatment groups using randomization by blocks. Block allocation sequences 
were created by using randomly generated numbers from a computer program." 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Unclear It is reported that the study was "double-blind". However, it is not reported whether the placebo was 
identical to the test drug in all important aspects (i.e. matched in terms of shape, size, colour, taste, and 
weight). 
Incomplete outcome 
data addressed? 
Yes No participants were lost to follow-up. 
Free of selective 
reporting? 
No Protocol not available; pre-specified outcomes not stated in the Methods section. 
Free of other bias? Unclear Funding source not reported. 
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Trebatická 2006  
Methods RCT; parallel group design. 
Ethics approval by the Ethical Committee of the Children University Hospital, Slovakia. 
Treatment duration: one month. 
Follow-up: one month after end of treatment, at the end of month two. 
Participants Total participants: 61 (44 in the treatment- and 17 in the control group). 
Country and setting: Slovakia, outpatients from the Department of Child Psychiatry at the Child University Hospital. 
Inclusion criteria: children with attention deficit hyperactivity disorder (ADHD) according to the International Statistical 
Classification of Diseases (ICD-10) which includes Hyperkinetic Disorder, Hyperkinetic Conduct Disorder, Attention 
Deficit without Hyperactivity; early onset of ADHD - chronicity by six to seven years of age; ADHD symptoms for at least 
six months; general disposition as restless, inattentive, distractible and disorganized; disorders of cognitive function 
("inattention, distractibility, difficulty to persist with any task, difficulty in selective process to information, disturbance of 
the executive functions, disturbance of motivation, effort and fortitude, visuospacial and memory disturbance"); 
disorders in control of activity ("inability to suppress activity, abnormality in control of activity, disorganisation and 
discontinuation of motoric activity"); impulsiveness ("acting without due reflection, engaging in rash and sometimes 
dangerous behaviour, disturbances or emotions and affectivity"). 
Exclusion criteria: situational hyperactivity; pervasive developmental disorders; schizophrenia; other psychotic disorders 
e.g. mood, anxiety, personality disorder as unsocial behaviour; personality change due to medical conditions; mental 
retardation; living in understimulating environments; conduct disorders; tics; chorea and other dyskinesias; acute 
inflammatory diseases; renal disorders; cardiovascular disorders; diabetes mellitus. 
Baseline characteristics: Treatment group: 84% males; "average" age 9.5 (range 6 to 14) years; "average" weight 35.28 
(unspecified measure of variation 10.13) kg; assumed mean BMI 17.41 (unspecified measure of variation 3.13) kg/m2. 
Control group: 76.5% males; "average" age 8.8 (range 6 to 12) years; "average" weight 34.80 (unspecified measure of 
variation 10.05) kg; assumed mean BMI 16.77 (unspecified measure of variation 2.61) kg/m2. 
Concomitant medication: none were permitted - neither psychotropic drugs nor vitamins E and C supplements during 
the study period. 
Diet: "Patients had a standard diet". 
Interventions Treatment: Pycnogenol; 1 mg/kg body weight at breakfast daily for one month. 
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Control: placebo identical in shape and appearance as the test drug; the same number of tablets as the test drug per 
day for one month. 
Route of administration: orally. 
Outcomes 
 Inattention symptom scores: collected at baseline, after one month of treatment, as well as at the end of the second 
month (one month after end of treatment); measured by teachers and parents by means of three different scales (i) 
Child Attention Problems Teacher Rating Scale (CAP), (ii) Conner's Teacher Rating Scale (CTRS), and (iii) the 
Conner's Parent Rating Scale (CPRS); the score at baseline for the CTRS were put to 100%, the raw scores were 
reported for CAP and CPRS. 
 Hyperactivity symptom scores: collected at baseline, after one month of treatment, as well as at the end of the second 
month (one month after end of treatment); measured by teachers and parents by means of three different scales (i) 
CAP, (ii) CTRS, and (iii) CPRS; the score at baseline for the CTRS were put to 100%, the raw scores were reported 
for CAP and CPRS. 
 Visual-motoric coordination and concentration: collected at baseline, after one month of treatment, as well as at the 
end of the second month (one month after end of treatment); "weight score" percentage were evaluated by 
psychologists and the score at baseline were put to 100%; "weight score" is the sum of values of five subtests of the 
Performance Scale for each participant, where a higher score represents a better psychological state. 
 Urine catecholamine concentration (adrenaline, noradrenaline, dopamine): collected at baseline, after one month of 
treatment, as well as at the end of the second month (one month after end of treatment); analysed by HPLC using 
electrochemical detection; expressed in percentage. 
 Urine creatinine concentration: collected at baseline, after one month of treatment, as well as at the end of the second 
month (one month after end of treatment); analysed using a commercial kit (DOT Diagnostics, Czech Republic) on 
Hitachi 911 automatic analyser (Roche); expressed in mmol/l. 
 Total glutathione concentration, oxidized glutathione concentration (GSSG) and GSH (reduced glutathione)/GSSG: 
total glutathione and GSSG in whole blood was determined by gradient HPLC; GSH was calculated according to the 
following formula: [GSH] = [total glutathione] - (2 × [GSSG]). 
 Safety by means of basic biochemical parameters (bilirubin, glucose, gamma-glutamyl transferase, alkaline 
phosphatase, aspartate aminotransferase, alanine aminotransferase, uric acid and lipid profile): collected at baseline, 
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after one month of treatment, as well as at the end of the second month (one month after end of treatment); analysed 
in plasma by standard biochemical procedures using the Hitachi 911 automatic analyser (Roche, Switzerland). 
 "Side effects": not reported how it were monitored, we assumed that the parent, care-taker or teacher reported 
observed "side effects" to the investigator during the two months study period. 
Notes Funding source: "This study was supported by Horphag Res. Ltd. grant, partly by VEGA Grants No. 1/1157/04, 
1/3037/06, Grant VV MVTS 03/LF of Ministry of Education of SR, by Drug Research Institute, Modra, SR and 
Mind&Health, civil association." 
 
Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Yes Computer generated random numbers; ratio of Pycnogenol:placebo was 2.5:1. 
Allocation 
concealment? 
Unclear Not reported. 
Blinding? Yes It is reported that the study was "double-blind". This was confirmed by the following quote: 
"Teachers, parents and physicians were not aware of results of randomization." 
Incomplete outcome 
data addressed? 
Unclear "Data of all patients were evaluated according ‘intention-to-treat’ analysis". However, it is not reported what 
they mean with 'intention-to-treat' analysis, i.e. how they handled the missing data. 3/44 participants of the 
treatment group and 1/17 of the control group were lost to follow-up. No reasons for withdrawal were 
reported. 
Free of selective 
reporting? 
No No protocol available; pre-specified outcomes no stated in the Methods section. 
Free of other bias? Unclear The study was, amongst others, funded by Horphag Research Ltd. This company is the manufacturer and 
holder of Pycnogenol's registered trademark. 
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Zibadi 2008  
Methods RCT; parallel group design. 
Ethics approval by the institutional review board of the University of Arizona, USA. 
Treatment duration: 12 weeks. 
No follow-up after end of treatment. 
Participants Total participants: 48 (24 in each group). 
Country and setting: Tuscon, Arizona, USA; participants recruited through newspaper advertising. 
Inclusion criteria: adult type II diabetics (40 to 75 years old) with hypertension (baseline systolic blood pressure of 130 
to 150 mm Hg); receiving angiotensin-converting enzyme (ACE) inhibitor for hypertension. 
Exclusion criteria: type I diabetes; on insulin treatment; use of supplements apart from one multivitamin daily; other 
major diseases e.g. cancer, asthma, heart failure; previous heart problems; pregnant or breastfeeding. 
Baseline characteristics: Treatment group: 54% males; mean age 61.3 (SEM 9.1) years; mean duration of diabetes 
mellitus 12.9 (SEM 11.6) years; mean pretrial systolic blood pressure 139.0 (SEM 1.3) mm Hg. Control group: 58% 
males; mean age 58.4 (SEM 11.5) years; mean duration of diabetes mellitus 14.2 (SEM 8.5) years; mean pretrial 
systolic blood pressure 137.0 (SEM 1.0) mm Hg. 
Concomitant medication: first generation sulfonylureas, second generation sulfonylureas, metformin, and 
thiazolidinediones for glucose control were permitted. 
Interventions Treatment: Pycnogenol; 25 mg tablets five times per day for 12 weeks. 
Control: placebo that "matched" the test drug; for 12 weeks. 
Route of administration: orally. 
Outcomes 
 ACE inhibitor dosage: dosage were either left unchanged (equal to baseline dose), reduced by 50% or brought back to 
the baseline dosage until a "stable blood pressure" was obtained; adjustments were made every two weeks after the 
systolic and diastolic blood pressure measurements were taken; expressed in percentage participants who could 
achieve blood pressure control with a 50% reduction in pretrial dose of ACE inhibitors at week 12. Blood pressure was 
measured at baseline and then at two week intervals up to week 12; measured in mm Hg on the left arm after a ten 
minute rest; three repeated readings at an interval of two minutes were taken while sitting, and the average recorded; 
Korotkoff I and V were taken as the systolic and diastolic blood pressures respectively; dosage of ACE inhibitor was 
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changed according to the systolic blood pressure measurements. 
 Heart rate: collected at baseline and then at two week intervals up to week 12; heart rate was "measured on the left 
arm after 10-minute rest". 
 Participants' treatment compliance: collected at the end of week four, eight and 12; unused pills were collected from 
participants and counted; reported in percentage. 
 Endothelin-1 levels: collected at baseline and at the end of week four, eight and 12 after fasting for eight hours; 
quantified in duplicate samples by ELISA (R&D Systems, Minneapolis, Minn); measured in pg/dl. 
 LDL-cholesterol levels: collected at baseline and at the end of week four, eight and 12 after fasting for eight hours; 
measured by the cholesterol esterase-cholesterol peroxidase coupling method; measured in mg/dl. 
 HbA1c levels: collected at baseline and at the end of week four, eight and 12 after fasting for eight hours; measured by 
inhibition of latex agglutination; reported in percentage. 
 Blood glucose levels: collected at baseline and at the end of week four, eight and 12 after fasting for eight hours; 
measured by double-enzyme assay with hexokinase and glucose-6-phosphate dehydrogenase using an Olympus 
AU640 analyser (Olympus America, Inc, Melville, New York); measured in mg/dl. 
 Urinary albumin concentration: data at baseline and at the end of week four, eight and 12; the semi-qualitative 
screening dipstick test were used on spot urine samples; reported in mg/l. 
 Adverse events: collected at "follow-up visits" (at the end of week four, eight and 12); collected from participants by 
means of questioning. 
 Safety monitoring: heart rate and change in use of concomitant antidiabetic medication were monitored to make sure 
that it stayed the same and had no effect on the study outcomes as confounder. 
Notes Funding source: "This study was supported by a research grant of Horphag Research. This funding had no role in the 
collection, analysis, and interpretation of data or in the writing of the manuscript." 
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Risk of bias table  
Item Judgement Description 
Adequate sequence 
generation? 
Unclear 
"...subjects were randomly assigned...". However, the randomisation method is not reported.  
Allocation 
concealment? 
Unclear Not reported.  
Blinding? Unclear It is reported that the study was "double-blind" and that the placebo "matched" the test drug. It is not clear 
what characteristics were matched. The test drug is known to have a bitter, astringent taste. 
Incomplete outcome 
data addressed? 
Unclear "Analysis was performed according to the intention to treat principle. Thus, all randomized patients who 
received at least 1 dose of study treatment and who had both a baseline and at least 1 postbaseline 
measurement were analyzed." However, it is not reported how missing data were handled. 1/24 
participants from the treatment and 2/24 from the control group were lost to follow-up.  
Free of selective 
reporting? 
No Protocol is available on the WHO's International Clinical Trials Registry Platform under the ID 
ISRCTN44961472. All outcomes specified in the protocol are addressed in the published article. However, 
there are outcomes in the article that are not pre-specified in the protocol: ACE inhibitor dosage (as the 
indirect measurement of systolic blood pressure) and adverse events. 
Free of other bias? Unclear The study was funded by Horphag Research Ltd. This company is the manufacturer and holder of 
Pycnogenol's registered trademark. 
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Characteristics of excluded studies  
Belcaro 2006b  
Reason for exclusion Prevention. 
 
Belcaro 2008a  
Reason for exclusion Not a RCT (although the participants are a subsample of a RCT, they are chosen according to their C-
reactive protein status and not at random). 
 
Cesarone 2006a  
Reason for exclusion Not a RCT. 
 
Cesarone 2006b  
Reason for exclusion Inappropriate control. 
 
Cesarone 2006c  
Reason for exclusion Not a RCT. 
 
Cesarone 2010  
Reason for exclusion Inappropriate control. 
 
Chovanová 2006  
Reason for exclusion Inappropriate outcomes (only antioxidant biomarkers were assessed). 
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Dvoáková 2006  
Reason for exclusion Inappropriate outcomes (only antioxidant biomarkers were assessed). 
 
Koch 2002  
Reason for exclusion Inappropriate control. 
 
Kohama 2004  
Reason for exclusion Not a chronic disorder. 
 
Kohama 2007  
Reason for exclusion Inappropriate control. 
 
Liu 2004b  
Reason for exclusion Not a RCT. 
 
Ni 2002  
Reason for exclusion Not a RCT (no control group). 
 
Spadea 2001  
Reason for exclusion Not a RCT (only half of the participants were randomised; results were not reported separately). 
 
Stefanescu 2001  
Reason for exclusion Not a RCT. 
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Suzuki 2008  
Reason for exclusion Not a chronic disorder. 
 
Wilson 2010  
Reason for exclusion Prevention. 
 
Yang 2007  
Reason for exclusion Not a RCT. 
 
Characteristics of studies awaiting classification  
Enseleit 2010  
Methods "Randomized, double-blind, placebo-controlled crossover study". 
Treatment duration: eight weeks per arm. 
Wash-out period: two weeks. 
Participants "25 patients with coronary artery disease". 
Interventions Treatment: Pycnogenol (200 mg per day) plus standard cardiovascular therapy. 
Control: placebo plus standard cardiovascular therapy. 
Outcomes At baseline and after each treatment arm the following outcomes were assessed: endothelial function, non-invasively 
assessed by flow-mediated dilation of the brachial artery; platelet adhesion; baroreceptor function; 24-hour blood 
pressure; plasma 8-isoprostanes (index of oxidative stress). 
Notes As far as we are aware, only the abstract and accompanying poster is available. Therefore the information we have for 
this study is limited. 
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Characteristics of ongoing studies  
ISRCTN22412590  
Study name Pilot study for the treatment of heart failure with Pycnogenol. 
Methods "...randomised, double-blind placebo-controlled matched pairs study". 
Target sample size: 30. 
Participants Inclusion criteria 
Patients > 40 years of age with chronic congestive heart failure [New York Heart Association (NYHA) class II], known 
for at least six months which were previously untreated or treated with a diuretic and/or a low dose of an ACE inhibitor; 
must have an exercise capacity of at least 75 watts (W) as assessed by seated bicycle ergometry. 
Exclusion criteria 
NYHA class I, III, or IV; treatment with digitalis within the previous six months; exercise capacity of > 75 W for two 
minutes at the test during run in; unstable angina or myocardial infarction within the last six months; atrial fibrillation or 
ventricular arrhythmia greater than or equal to "Lown III"; cardiac valvular disease or hypertrophic cardiomyopathy; 
significant hypertension or hypotension (diastolic blood pressure < 60 mm Hg or  105 mm Hg, or systolic blood 
pressure < 90 mm Hg or > 175 mm Hg); electrolyte disturbances, hyperuricaemia, hypovolaemia; impaired renal 
function (creatinine levels > 1.8 mg/dl) or impaired hepatic function; obstructive airways disease; insulin-dependent 
diabetes mellitus; malignant or other serious disease; hypersensitivity to the study drug Pycnogenol; pregnant, 
unreliable contraception, breastfeeding; participation in another clinical trial within the last six weeks. 
Interventions Intervention: Pycnogenol, 200 mg (assumed) daily; for 12 weeks. 
Control: placebo; for 12 weeks. 
Outcomes Primary outcomes 
Tests for maximal workload and pressure-heart product at baseline, as well as the end of week four, eight and 12 of 
treatment. Maximal workload will be determined by a symptom-limited bicycle exercise test in the seated position. 
Pressure-heart rate product entails the measurement of systolic blood pressure and heart rate immediately after two 
minutes of work at 50 W; it is calculated by units of systolic blood pressure (mm Hg) × heart rate per minute divided by 
100. 
Secondary outcomes 
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Participant-reported symptom scores for dyspnoea and fatigue for the foregoing four weeks upon enrolment (baseline), 
as well as at the end of week four, eight and 12 of treatment. Symptom scores will be evaluated by asking patients 
about the severity of the following symptoms: early fatigability, dyspnoea, general capability, lassitude, feeling 
depressed, and anxiety. The scores range as follows: 0 = not present, 1 = occasionally mild, 2 = frequently mild, 3 = 
moderate, 4 = severe. 
Biochemical tests: C-reactive protein, troponin T, and B-type natriuretic peptide (BNP) (specifically NT-proBNP); not 
reported how frequent these blood analysis were to be done. 
Starting date 10 August 2007. 
Contact information A Matsumori; no email address reported; Kyoto University Graduate School of Medicine, Department of Cardiovascular 
Medicine, Sakyo-ku, Kyoto, Japan, 6068507. 
Notes Country: Japan. 
Status of study: "Completed". 
Sponsor: Kyoto University Graduate School of Medicine, Cardiomyopathy and Myocarditis Research Fund, Japan; 
website http://www.kyoto-u.ac.jp/index-e.html.  
 
NCT00064857  
Study name Pycnogenol for the treatment of lymphedema of the arm in breast cancer survivors. 
Methods "Randomized, placebo control, efficacy study, parallel assignment, double-blind". 
Estimated enrolment: 26. 
Participants Inclusion criteria 
Both genders 18 years and older with unilateral (ipsilateral to breast cancer resection side) lymphedema of the upper 
extremity; extravascular water ration of > 1.07/1 between affected versus normal arm using multiple frequency 
bioelectric impedence; last surgical or radiation treatment to the affected axilla was more than two months ago; the 
following renal and hepatic function: creatinine clearance > 50 ml/min, total bilirubin < 2 mg/dl, transaminases < 1.5 × 
ULN (upper limit of normal); not pregnant or breastfeeding, and use of barrier contraception if sexually active; Eastern 
Cooperative Oncology Group (ECOG) performance of 0 to 2; not allergic to Pycnogenol. 
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Exclusion criteria 
Treated with first course of chemotherapy or radiation; chemotherapy or radiation to axillary lymph node will exclude 
patients for eight weeks following treatment; more than one episode of arm cellulitis, venous clot, or woody fibrosis of 
the affected arm (antibiotics used to treat cellulitis must be completed at least four weeks prior to initial screening); 
patients with a defibrillator Midazolam study only: patiens requiring or benefiting from supplemental oxygen, patients 
allergic to cherries. 
Interventions Intervention: Pycnogenol; no detail reported. 
Control: placebo; no detail reported. 
Outcomes Outcomes are not explicitly reported nor grouped into primary and secondary outcomes. However, the planned 
measurements are reported: 
Comparison of the correlation of both a single- and a multiple-frequency bioelectric impedance instrument in measuring 
change in arm volume to a standard assessment using water displacement; 
Use a small oral dose of midazolam and single blood sampling to screen for effects of Pycnogenol on the activity of the 
common drug metabolizing enzyme CYP3A4; 
Use digoxin urine excretion to screen for effects of the test drug upon the activity of P-glycoprotein in the subjects 
already receiving digoxin; and 
Evaluation of a new questionnaire of lymphedema symptoms presently begin tested as a tool for assessing the severity 
and improvement of symptoms with treatment. 
Starting date August 2003. 
Contact information JF Cleary; no email address provided; University of Wisconsin, Madison, Wisconsin, United States, 53706. 
Notes Country: USA. 
Status of study: "This study has been completed." 
Sponsors and collaborators: National Center for Complementary and Alternative Medicine (NCCAM). 
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NCT00214032  
Study name Pycnogenol for the treatment of lymphedema. 
Methods "Randomized, active control, safety/efficacy study, single group assignment, double blind". 
Enrolment: "2"; we suppose this is a mistake. 
Participants Inclusion criteria 
Females of 18 years and older who have unilateral lymphedema of the upper extremity; received more than six months 
ago surgical and/or radiation treatment to the effected axilla. 
Exclusion criteria 
Participants may not receive or be scheduled to receive cytotoxic or radiation chemotherapy treatment while part of the 
study. 
Interventions Intervention: Pycnogenol; 300 mg daily; duration not reported. 
Control: placebo; 3 capsules daily; duration not reported. 
Outcomes Primary outcome 
Reduction of arm lymphedema: measured monthly. 
Secondary outcomes 
"Comparison/validation of bioelectric impedance to measure lymphedema changes, validation of lymphedema 
questionnaire": evaluated monthly. 
Starting date March 2002. 
Contact information PR Hutson; no email address provided; University of Wisconsin, Madison, Wisconsin, USA, 53792. 
Notes Country: USA. 
Status of study: "This study has been completed." 
Sponsors and collaborators: University of Wisconsin, Madison; National Center for Complementary and Alternative 
Medicine (NCCAM). 
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NCT00952627  
Study name Effects of Pycnogenol on cardiac fibrosis and diastolic dysfunction in aged hypertensive subjects. 
Methods "Randomized, placebo control, efficacy study, parallel assignment, double blind". 
Estimated enrolment: 40. 
Participants Inclusion criteria 
Both genders aged between 50 and 75 years of any race diagnosed with hypertension (diagnosis made over six 
months) and echocardiographic evidence of grade I or II diastolic dysfunction. 
"There is no need for standardization of hypertension treatment, as we select only patients who have diastolic 
dysfunction during treatment." 
Exclusion criteria 
Unstable angina or myocardial infarction in the past three months; biochemical evidence of renal or hepatic failure; 
severe anaemia (defined as haemoglobin levels < 7 g/dl); current cancer or other major illness not associated with the 
heart; bleeding disorders; taking anticoagulants including low dose aspirin; diabetes; known allergy to Pycnogenol; 
pregnant or breastfeeding; systolic blood pressure > 180 mm Hg or < 100 mm Hg, and diastolic blood pressure >110 
mm Hg or < 50 mm Hg; current smoking; having breast implants; taking any of the following: birth control pills, 
diethylstilbestrol, Ephedra, ephedrine or pseudoephedrine (except where used in prescription products), hormone 
replacement products, Isotretinoin, any product containing mercury, Phentermine in combination with fenfluramine 
(including but not limited to Pondimin), or dexfenfluramine (Redux). 
Interventions Intervention: Pycnogenol; 50 mg tablets, four tablets per day; for four months. 
Control: placebo; no detail provided; for four months. 
Outcomes Primary outcomes 
Cardiac fibrosis: measured as the serum markers of myocardial fibrosis and collagen turnover; collected at baseline and 
after four months of treatment. 
Diastolic dysfunction: measured by transthoracic echocardiogram; collected at baseline and after four months of 
treatment. 
Secondary outcomes 
Liver and kidney function tests: collected at baseline and after four months of treatment. 
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Immunological measurements including the cytokine profile in serum (interleukin-4, interleukin-10, interferon-gamma, C-
reactive protein): collected at baseline and after four months of treatment. 
Starting date July 2009. 
Contact information RR Watson; rwatson@u.arizona.edu; University of Arizona, USA, 85724. 
Notes Country: USA. 
Status of study: "This study is currently [August 2009] recruiting participants". 
Sponsors and collaborators: University of Arizona; Horphag Research, Switzerland. 
 
Additional tables 
Table 1: Additional assessment of risk of bias in included crossover trials  
Study ID Criteria Yes/No/Unclear Comments 
Hosseini 
2001a 
Is the crossover design 
suitable? Yes 
 
 
Was there no carry-over 
effect? Unclear 
There was no wash-out period between the treatment and control periods; no tests 
were performed for assessing period effect, treatment-period interaction, or carry-over 
effect. 
 
Are data of both periods 
available? Unclear Not reported. 
 
Was a paired analysis 
being used? Yes 
"Paired two-tailed t-test", "Friedman measures analysis of variance on ranks", "student-
Newman-Keuls". 
 
Are the results comparable 
to those from parallel group 
trials? 
Unclear 
There is one included parallel group design RCT on asthma. However, the participants 
in that trial were children between 6 and 18 years old. We cannot compare that results 
with the results of this crossover trial on asthmatic adults (18 to 60 years old). 
Hosseini 
2001b 
Is the crossover design 
suitable? Yes 
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Was there no carry-over 
effect? Unclear 
There was no wash-out period between the treatment and control periods; no tests 
were performed for assessing period effect, treatment-period interaction, or carry-over 
effect. 
 
Are data of both periods 
available? Yes 
Not reported directly, but it is mentioned in the small print beneath the figures that "all 
11 subjects data are analysed". 
 
Was a paired analysis 
being used? Yes Paired t-test. 
 
Are the results comparable 
to those from parallel group 
trials? 
Unclear The same outcomes were not addressed. 
 
 
Table 2: Incomplete results: Hosseini 2001a and Lau 2004  
Study ID Outcome 
Pycnogenol Placebo Pycnogenol versus placebo 
Baseline 
Mean (SE) 
Month 3 
Mean (SE) 
Baseline 
Mean (SE) 
Month 3 
Mean (SE) Mean difference (SE) 
Hosseini 2001a Asthma symptom scores # 1.75* (#) # 2.15* (#) # 
Lau 2004 Asthma symptom scores 2.25 (0.13) 0.27 (0.06) # # # 
Lau 2004 Peak expiratory flow 69.7 (1.7)  69.9 (1.6)  # 
Lau 2004 Use of albuterol inhaler (puffs/24 hours) 2.57 (0.16) 0.22 (0.07) 2.59 (0.14) 2.32 (0.21) # 
# Not reported 
* Extracted from figure 
 Only reported in figure from which results cannot be extracted accurately 
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Table 3:  Incomplete results: Dvoáková 2007  
Outcome 
Pycnogenol Placebo Pycnogenol versus placebo 
Baseline 
Mean (SE) 
Month 1 
Mean (SE) 
Baseline 
Mean (SE) 
Month 1 
Mean (SE) Mean difference (SE) 
GSH/GSSG 35.93 (4.27)^ 52.26 (3.81) 35.93 (4.27)^    # 
 
 "No changes in GSH/GSSG ratio were found in response to placebo treatment." 
# Not reported 
^ "In patients with ADHD, the calculated GSH/GSSG ratio was 35.93±4.27 at the beginning of the trial." 
 
 
Table 4: Incomplete results: Arcangeli 2000 and Petrassi 2000  
Study ID Outcome 
Pycnogenol Placebo Pycnogenol versus placebo 
Baseline 
Mean (SE) 
Month 2 
Mean (SE) 
Baseline 
Mean (SE) 
Month 2 
Mean (SE) Mean difference (SE) 
Arcangeli 2000 Heaviness score 2.06 (0.13) 0.94 (0.19) 1.72 (0.11) 1.67 (0.11) 1.07 (#) 
 
Swelling score 1.68 (0.13) 0.60 (0.21) 1.50 (0.12) 1.39 (0.12) 0.97 (#) 
 
Pain score 1.61 (0.12) 0.58 (0.19) 1.42 (0.15) 1.17 (0.11) 0.78 (#) 
Petrassi 2000 Heaviness score 2.22 (0.222) 0.88 (0.227) 1.83 (0.167) 1.60 (0.245) 1.11 (#) 
 
Swelling score 1.25 (0.164) 0.33 (0.333) 1.00 (0.00) 0.71 (0.184) 0.63 (#) 
 
Pain score # # # # # 
# Not reported 
 
 
77 
 
Table 5: Incomplete results: Belcaro 2006a  
Outcome 
Pycnogenol (oral & 
local) Pycnogenol (local) Pycnogenol (oral) Control 
Pycnogenol versus 
control 
Baseline 
Mean (SD) 
Week 6 
Mean (SD) 
Baseline 
Mean 
(SD) 
Week 6 
Mean 
(SD) 
Baseline 
Mean 
(SD) 
Week 6 
Mean 
(SD) 
Baseline 
Mean 
(SD) 
Week 6 
Mean 
(SD) 
Mean difference (SD) 
Microcirculation-related symptom 
scores 
7.0 (3.0) 2.2 (2.0) 7.1 (3.0) 4.0 (2.0) 7.2 (2.2) 3.8 (2.2) 7.1 (2.0) 5.1 (3.0) # 
Change in area of ulceration 
(mm2) 43.0 (4.0) 11.0 (4.0) 46.0 (6) 
27.0 
(7.0) 45.0 (4.0) 
30.0 
(6.0) 44.0 (5.2) 
35.0 
(5.0) # 
Transcutaneous PO2 47.0 (4.0) 58.0 (3.0) - - 46.0 (3.0) 55.0 (4.0) 48.0 (4.2) 
48.0 
(3.0) # 
Transcutaneous PCO2 33.0 (2.0) 27.0 (3.0) - - 32.0 (3.0) 28.8 (2.0) 32.0 (2.2) 
29.8 
(3.3) # 
Skin flux at rest 3.6 (1.0) 2.0 (0.7) - - 3.5 (0.7) 2.1 (1.0) 3.8 (0.2)  # 
# Not reported 
- Not assessed 

 Reported with an error (as "3.3.8"). We contacted the study authors and are awaiting their response. 
 
Table 6: Venoarteriolar response (LDF units): Belcaro 2006a  
Time point 
Pycnogenol (oral + local) 
Median (range) 
Pycnogenol (oral) 
Median (range) 
Control 
Median (range) 
Baseline 8 (0 to 20) 9 (0 to 21) 9 (0 to 19) 
Week 6 22 (5 to 38) 12 (4 to 32) 8 (3 to 23) 
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Table 7: Blood glucose (mmol/l) and plasma HbA1c (%): Liu 2004a  
Outcome Period 
Pycnogenol 
Median (IQR) 
Placebo 
Median (IQR) 
Pycnogenol versus 
placebo 
Blood glucose 
(mmol/l) Decrease at the end of week 12 relative to 
baseline 
-1.96 (-3.25 to -
1.24) 
-1.11 (-2.00 to -
0.44) P < 0.01 
HbA1c (%) -0.69 (-1.07 to -0.43) 
-0.53 (-0.75 to -
0.16) P > 0.05 
 
 
Table 8: Incomplete results: Zibadi 2008  
Outcome 
Pycnogenol Placebo Pycnogenol versus placebo 
Baseline 
Mean (SE) 
Week 12 
Mean (SE) 
Baseline 
Mean (SE) 
Week 12 
Mean (SE) Mean difference (SE) 
Glucose levels (mg/dl) 142.3 (9.8) 118.6 (9.5) 151.1 (12.1) 145.3 (11.4) 17.9 (#) 
HbA1c levels (%) 7.9 (0.3) 7.1 (0.2) 8.1 (0.4) 8.0 (0.4) 0.7 (#) 
Urinary albumin levels (mg/l) 29.6 (5.9) 22.2 (6.1) 37.4 (7.0) 36.1 (6.3) 6.1 (#) 
# Not reported 
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Table 9: Incomplete results: uraková 2003  
Outcome 
Pycnogenol Placebo Pycnogenol versus placebo 
Baseline 
Mean (SE) 
Month 3 
Mean (SE) 
Baseline 
Mean (SE) 
Month 3 
Mean (SE) Mean difference (SE) 
Erectile dysfunction score 12.6 (1.1) 16.8 (0.8) 11.3 (1.3) 8.9 (1.2) 6.6 (#) 
Antioxidant activity in the blood (%) 100 118* (#) 100 105* (#) # 
# Not reported 
* Extracted from figure 
 
 
Table 10: Incomplete results: Hosseini 2001b  
Outcome 
Pycnogenol Placebo Pycnogenol versus placebo 
Baseline 
Mean (SE) 
Week 8 
Mean (SE) 
Baseline 
Mean (SE) 
Week 8 
Mean (SE) Mean Difference (SE) 
Systolic blood pressure (mm Hg) 139.9 (3.3) 132.7 (4.18) # # # 
Diastolic blood pressure (mm Hg) 93.8 (1.23) 92.0 (1.7) # # # 
# Not reported 
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Table 11: Change in nitric oxide levels (nmol/l): Liu 2004c  
Period 
Pycnogenol 
Median (IQR) 
Placebo 
Median (IQR) 
Pycnogenol versus 
placebo 
% change in nitric oxide concentration at end of month 3 relative to 
baseline 
11.75 (-1.44 to 
32.08) 
10.50 (-2.07 to 
29.11) Ns (p-value not reported) 
Ns = Reported to be statistically non-significant 
 
 
Table 12: Incomplete results: Belcaro 2008b and Farid 2007  
Study ID Outcome 
Pycnogenol Placebo Pycnogenol versus placebo 
Baseline 
Mean (SD) 
Month 3 
Mean (SD) 
Baseline 
Mean (SD) 
Month 3 
Mean (SD) Mean difference (SD) 
Belcaro 2008b Sum of pain scores 17.3 (#) 7.7 (#) 17.1 (#) 15.2 (#) # 
Farid 2007 Pain score 292 (101) 164 (72) 301 (119) 306 (103) 133 (#) 
Belcaro 2008b Sum of stiffness scores 6.6 (#) 3.1 (#) 6.7 (#) 6.7 (#) # 
Farid 2007 Stiffness score 110 (66) 75 (54) 120 (63) 108 (56) 23 (#) 
Belcaro 2008b Sum of physical function scores 55.3 (#) 23.8 (#) 53.1 (#) 47.6 (#) # 
Farid 2007 Physical function score 997 (352) 485 (259) 1042 (420) 1014 (385) 484 (#) 
Belcaro 2008b Global WOMAC score 79.2 (#)) 34.6 (#) 76.9 (#) 69.5 (#) # 
Farid 2007 Composite WOMAC score 1400 (482) 725 (346) 1463 (552) 1455 (509) 667 (#) 
Belcaro 2008b Negative alterations in social functions 23.1 (#) 9.9 (#) 21.3 (#) 20.4 (#) # 
Belcaro 2008b Emotional parameters 31.4 (#) 11.5 (#) 28.2 (#) 24.4 (#) # 
# Not reported 
81 
 
Table 13: Incomplete results: Cisár 2008  
Outcome 
Pycnogenol Placebo Pycnogenol versus placebo 
Baseline 
Median 
(IQR) 
Week 12 
Median 
(IQR) 
Median 
change (p-
value) 
Baseline 
Median 
(IQR) 
Week 12 
Median 
(IQR) 
Median 
change (p-
value) 
Mean 
change 
Statistical 
significance 
Pain reduction (WOMAC A score) 14* (#) 16* (#) 2 (p = 0.001) 14* (#) 16* (#) 2 (#) 0 Ns 
Pain reduction (VAS) 37.5* (#) 22.5 (#) 15 (p = 0.058) 43.5* (#) 27* (#) 16.5 (#) -1.5 Ns 
Stiffness reduction in % (WOMAC B 
score) 100* 120* 20 (P < 0.01) 100* 100* 0 (Ns) 20 # 
Ability to perform daily activities 
(WOMAC C score) 46* (#) 53* (#) 7 (p = 0.01) 44* (#) 50* (#) 6 (Ns) 1 # 
Overall reduction in osteoarthritis 
symptoms (WOMAC overall score) 65* (#) 75* (#) 10 (p = 0.03) 64* (#) 72* (#) 8 (p = 0.02) 2 # 
* Extracted from figure 
# Not reported 
Ns = Reported to be statistically non-significant 
 
 
Table 14: Physical performance on treadmill (meters): Belcaro 2008b  
Time point 
Pycnogenol 
Mean (range) 
Placebo 
Mean (range) Pycnogenol versus placebo 
Baseline 68 (0 to 133) 65 (12 to 98) Ns 
Month 3 198 (55 to 374) 88 (25 to 102) P < 0.05 
Ns = Reported to be statistically non-significant 
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Table 15: Safety  
Study ID Country Number of participants 
Adults 
or 
children 
Chronic 
disorder 
Treatment 
duration Serious adverse events Non-serious adverse events 
Arcangeli 
2000 Italy 40 Adults CVI 2 months None found None found 
Belcaro 
2006a Italy 30 Adults Diabetes 6 weeks None found None found 
Belcaro 
2008b Italy 156 Adults 
Osteoarthritis 
of the knee 3 months 
Only the perceived protective effect that the treatment had on 
“unwanted effects” attributed to NSAIDs use was measured. 
Cisár 2008 Slovakia 100 Adults Osteoarthritis 
of the knee 12 weeks 
2/50 participants from the 
Pycnogenol group and 5/50 
from the placebo group left the 
study because they didn't want 
to use the treatment they've 
received anymore. 
1 participant (with previous 
myocardial infarction) from the 
Pycnogenol group left the study 
because of chest pain; another 
left because of bad breath. 3 
participants from the placebo 
group left because of worsening 
pain, 1 because of gastric pain 
and another 1 felt ill. 
None found 
Farid 2007 Iran 37 Adults Osteoarthritis 
of the knee 3 months None found None found 
Hosseini 
2001a Iran 26 Adults Asthma four weeks None found 
One participant complained of 
gastrointestinal disturbances which 
occurred within the first 3 to 4 days of 
treatment (assumed to be 
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Pycnogenol). 
Hosseini 
2001b USA 11 Adults Hypertension 8 weeks None found None found 
Lau 2004 USA 60 Children Asthma 3 months None found None found 
Liu 2004a China 77 Adults Diabetes 12 weeks None found 
7/34 participants in the Pycnogenol 
group complained about dizziness 
compared to 4/43 in the placebo 
group. 5/34 participants in the 
Pycnogenol group reported gastro-
intestinal problems compared to 2/43 
in the placebo group. "Other 
complaints of headache, nausea and 
sleepiness occurred only in one or two 
patients in both groups." 
Liu 2004c China 58 Adults Hypertension 12 weeks None found 
"Gastrointestinal problems, nausea, 
dizziness, headache and sleepiness 
had been reported. The difference in 
the rate of side effects in Pycnogenol 
group (39%) and in placebo group 
(27%) was not statistically significant." 
Petrassi 
2000 Italy 20 Adults CVI 2 months None found None found 
Steigerwalt 
2009 Italy 46 Adults Diabetes 2 months None found None found 
Trebatická 
2006 Slovakia 61 Children ADHD 1 month 
None found although 2/43 
participants withdraw from the 
study "even though they 
received medication" 
(Pycnogenol). 1/17 participant 
from the placebo group 
1/44 participant in the Pycnogenol 
group reported a "rise in slowness"; 
another reported moderate gastric 
discomfort. No adverse events in the 
placebo group (N = 17) were reported. 
84 
 
discontinued participation in the 
study. It is not reported what the 
reason(s) for withdrawal were. 
Zibadi 
2008 USA 48 Adults Diabetes 12 weeks None found None found 
uraková 
2003 
Slovak 
Republic 21 Adults ED 3 months Not assessed Not assessed 
 
 
Table 16: Evaluating the methodological quality of systematic reviews with the AMSTAR tool (Shea 2007)  
Criteria 
Yes/No/Can't answer/Not applicable 
Bartlett 2008 Clark 2010 Henrotin 2010 
Our 
Pycnogenol 
review 
1. Was an 'a priori' design provided? 
- The research question and inclusion 
criteria should be established before the 
conduct of the review. 
Yes Yes Yes Yes 
2. Was there duplicate study selection 
and data extraction? 
- There should be at least two 
independent data extractors and a 
consensus procedure for disagreements 
should be in place. 
No Yes No Yes 
3. Was a comprehensive literature 
search performed? 
- At least two electronic sources should 
be searched. The report must include 
Yes Yes No Yes 
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years and databases used (e.g. 
CENTRAL, EMBASE and MEDLINE). 
Key words and/or MESH terms must be 
stated and where feasible the search 
strategy should be provided. All 
searches should be supplemented by 
consulting current contents, reviews, 
textbooks, specialized registers or 
experts in the particular field of study, 
and by reviewing the references in the 
studies found. 
4. Was the status of publication (i.e. grey 
literature) used as an inclusion criterion? 
- The authors should state that they 
searched for reports regardless of their 
publication type. The authors should 
state whether or not they excluded any 
reports (from the systematic review), 
based on their publication status, 
language etc. 
No Can't answer Yes No 
5. Was a list of studies (included and 
excluded) provided? 
- A list of included and excluded studies 
should be provided. 
No 
Yes. 
A list of excluded 
studies was not 
provided, but they've 
presented the number 
of excluded studies 
per reason in a flow 
chart. 
No Yes 
6. Were the characteristics of the 
included studies provided? 
- In an aggregated from such as a table, 
data from the original studies should be 
No, it is incomplete. Yes No, it is incomplete. Yes 
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provided on the participants, 
interventions and outcomes. The ranges 
of characteristics in all the studies 
analysed e.g. age, race, sex, relevant 
socioeconomic data, disease status, 
duration, severity or other diseases 
should be reported. 
7. Was the scientific quality of the 
included studies assessed and 
documented? 
- 'A priori' methods of assessment 
should be provided (e.g. for 
effectiveness studies if the author(s) 
chose to include only randomised, 
double-blind, placebo controlled studies, 
or allocation concealment as inclusion 
criteria); for other types of studies 
alternative items will be relevant. 
No. It is reported that 
only "double-masked 
randomised controlled 
trials" were selected, but 
one of the three included 
studies (Spadea 2001) 
on Pycnogenol was not 
fully randomised. 
Yes. The Cochrane 
risk of bias 
assessment tool was 
used to evaluated 
adequate sequence 
generation, allocation 
concealment and 
blinding. 
Yes. "The methodological quality of each 
clinical...was determined according to an 
assessment model adapted from EFSA 
and FDA recommendations; AFSSA 
guidelines and other relevant 
references." This entails that the "quality 
is scored according to a set of 14 
criteria...one point is marked for each 
criterion presented in the description of 
the clinical trial." The total scores allow 
classification as follows: < 6 poor; 7 to 9 
medium; 10 to 11 good; and 12 to 14 
very good methodological quality. 
Yes 
8. Was the scientific quality of the 
included studies used appropriately in 
formulating conclusion? 
- The results of the methodological rigor 
and scientific quality should be 
considered in the analysis and the 
conclusions of the review, and explicitly 
stated in formulating recommendations. 
No Yes 
Yes, however we do not agree with their 
judgement of "good to very good" 
methodological quality. 
Yes 
9. Were the methods used to combine 
the findings of studies appropriate? 
- For the pooled results, a test should be 
done to ensure the studies were 
Not applicable Yes Not applicable Yes 
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combinable, to assess their homogeneity 
(i.e. Chi2 test for homogeneity, I2). If 
heterogeneity exists a random effects 
model should be used and/or the clinical 
appropriateness of combining should be 
taken into consideration (i.e. is it 
sensible to combine?). 
10. Was the likelihood of publication bias 
assessed? 
- An assessment of publication bias 
should include a combination of 
graphical aids (e.g. funnel plot, other 
available tests) and/or statistical tests 
(e.g. Egger regression test). 
Not applicable Not applicable Not applicable Not 
applicable 
11. Was the conflict of interest stated? 
- Potential sources of support should be 
clearly acknowledged in both the 
systematic review and the included 
studies. 
No Yes Yes Yes 
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Data and analyses 
 
Comparison 1: Pycnogenol versus placebo: Asthma  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
1.1 Decrease of asthma symptoms 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.85 [1.32, 2.58] 
1.2 Patients off albuterol inhaler 1 60 Risk Ratio (M-H, Fixed, 95% CI) 6.00 [1.97, 18.25] 
1.3 Number of albuterol inhaler puffs per 
24 hours 
1 60 Mean Difference (IV, Fixed, 95% CI) -2.10 [-2.53, -1.67] 
1.4 Change in FEV1 1  Mean Difference (IV, Fixed, 95% CI) 7.00 [0.10, 13.90] 
1.5 Change in FEV1/FVC 1  Mean Difference (IV, Fixed, 95% CI) 7.70 [3.19, 12.21] 
  
 
Comparison 2: Pycnogenol versus placebo: Attention deficit hyperactivity disorder  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
2.1 Change in inattention as measured by 
CAP scores 
1  Mean Difference (IV, Fixed, 95% CI) 2.00 [0.61, 3.39] 
2.2 Change in hyperactivity as measured 
by CAP scores 
1  Mean Difference (IV, Fixed, 95% CI) 2.00 [0.10, 3.90] 
2.3 % change in inattention as measured 
by CTRS 
1  Mean Difference (IV, Fixed, 95% CI) 14.00 [0.34, 27.66] 
2.4 % change in hyperactivity as 
measured by CTRS 
1  Mean Difference (IV, Fixed, 95% CI) 4.00 [-3.19, 11.19] 
2.5 Hyperactivity as measured by CPRS 
scores 
1  Mean Difference (IV, Fixed, 95% CI) -3.50 [-7.15, 0.15] 
2.6 % change in visual-motoric 
coordination and concentration 
1  Mean Difference (IV, Fixed, 95% CI) 8.00 [0.16, 15.84] 
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Comparison 3: Pycnogenol versus placebo: Chronic venous insufficiency 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
3.1 Heaviness scores 2 60 Mean Difference (IV, Fixed, 95% CI) -0.72 [-0.91, -0.54] 
3.2 Swelling scores 2 60 Mean Difference (IV, Fixed, 95% CI) -0.46 [-0.67, -0.25] 
3.3 Pain scores 1 40 Mean Difference (IV, Fixed, 95% CI) -0.59 [-1.02, -0.16] 
3.4 Disappearance of heaviness 1 40 Risk Ratio (M-H, Fixed, 95% CI) 15.00 [0.91, 246.20] 
3.5 Disappearance of swelling 1 40 Risk Ratio (M-H, Fixed, 95% CI) 27.00 [1.71, 425.36] 
3.6 Disappearance of pain 1 40 Risk Ratio (M-H, Fixed, 95% CI) 25.00 [1.58, 395.48] 
3.7 Treatment efficacy as judged by 
physician 
1 40 Risk Ratio (M-H, Fixed, 95% CI) 4.75 [1.97, 11.48] 
  
 
Comparison 4: Pycnogenol (oral) versus control: Insulin-dependent diabetes mellitus  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
4.1 Microcirculation-related symptom 
scores 
1 14 Mean Difference (IV, Fixed, 95% CI) -1.30 [-4.02, 1.42] 
4.2 Area of ulceration 1 14 Mean Difference (IV, Fixed, 95% CI) -4.00 [-9.92, 1.92] 
4.3 Transcutaneous PO2 1 14 Mean Difference (IV, Fixed, 95% CI) 7.00 [3.18, 10.82] 
4.4 Transcutaneous PCO2 1 14 Mean Difference (IV, Fixed, 95% CI) -1.00 [-3.79, 1.79] 
 
 
Comparison 5: Pycnogenol versus placebo: Diabetes mellitus type II  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
5.3 Glucose levels (mg/dl) 1 48 Mean Difference (IV, Fixed, 95% CI) -26.70 [-55.79, 2.39] 
5.4 HbA1c levels (%) 1 48 Mean Difference (IV, Fixed, 95% CI) -0.90 [-1.78, -0.02] 
5.5 Urinary albumin levels (mg/l) 1 48 Mean Difference (IV, Fixed, 95% CI) -13.90 [-31.09, 3.29] 
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Comparison 6: Pycnogenol versus placebo: Erectile dysfunction 
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
6.1 ED symptom scores 1 21 Mean Difference (IV, Fixed, 95% CI) 7.90 [5.08, 10.72] 
 
  
Comparison 7: Pycnogenol versus placebo: Hypertension  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
7.1 Reduction of nifedipine dose 1 58 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.83, 1.52] 
7.2 Using 10 mg nifedipine 1 58 Risk Ratio (M-H, Fixed, 95% CI) 4.29 [1.63, 11.27] 
  
 
Comparison 8: Pycnogenol versus placebo: Osteoarthritis of the knee  
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
8.1 Pain scores 1 37 Mean Difference (IV, Fixed, 95% CI) -142.00 [-199.55, -84.45] 
8.2 Stiffness scores 1 37 Mean Difference (IV, Fixed, 95% CI) -33.00 [-68.48, 2.48] 
8.3 Physical function score 1 37 Mean Difference (IV, Fixed, 95% CI) -529.00 [-741.59, -316.41] 
8.4 Composite WOMAC score 1 37 Mean Difference (IV, Fixed, 95% CI) -730.00 [-1011.95, -448.05] 
8.5 Reduction of NSAIDS 1 100 Risk Ratio (M-H, Fixed, 95% CI) 4.75 [1.74, 12.97] 
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Figures 
 
Figure 1: Flow diagram of search results 
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Figure 2: Review authors' judgements about each risk of bias item presented as percentages across all included studies 
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Figure 3: Review authors' judgements about each risk of bias item for each included  
     study 
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Figure 4 (Analysis 3.1): Forest plot of comparison: 3 Pycnogenol versus placebo: Chronic venous insufficiency, outcome: 3.1  
                                        Change in heaviness scores 
      
 
 
 
 
Figure 5 (Analysis 3.2): Forest plot of comparison: 3 Pycnogenol versus placebo: Chronic venous insufficiency, outcome: 3.2  
                                        Change in swelling scores 
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Appendices 
 
Appendix 1: MEDLINE search strategy  
 
1 Pycnogenol [tiab] 
2 pine bark [tiab] 
3 #1 OR #2 
4 randomized controlled trial [pt] 
5 controlled clinical trial [pt] 
6 randomized [tiab] 
7 placebo [tiab] 
8 drug therapy [sh] 
9 randomly [tiab] 
10 trial [tiab] 
11 groups [tiab] 
12 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 
13 animals [mh] NOT (humans [mh] AND animals [mh]) 
14 #12 NOT #13 
15 #3 AND #14 
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Appendix 2: CENTRAL search strategy  
 
1 (Pycnogenol):ti,ab,kw in Clinical Trials 
2 (pine bark):ti,ab,kw in Clinical Trials 
3 (#1 OR #2) 
4 (randomized controlled trial):pt in Clinical Trials 
5 (controlled clinical trial):pt in Clinical Trials 
6 (randomized):ti,ab,kw in Clinical Trials 
7 (placebo):ti,ab,kw in Clinical Trials 
8 (drug therapy):ti,ab,kw in Clinical Trials 
9 (randomly):ti,ab,kw in Clinical Trials 
10 (trial):ti,ab,kw in Clinical Trials 
11 (groups):ti,ab,kw in Clinical Trials 
12 (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11) 
13 (#3 AND #12) 
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Appendix 3: EMBASE search strategy  
 
1 random*:ti OR random*:ab OR factorial*:ti OR factorial*:ab OR cross?over:ti OR 
cross?over:ab OR crossover*:ti OR crossover*:ab OR placebo*:ti OR placebo*:ab OR 
(doubl*:ti AND blind*:ti) OR (doubl*:ab AND blind*:ab) OR (singl*:ti AND blind*:ti) OR 
(singl*:ab AND blind*:ab) OR assign*:ti OR assign*:ab OR volunteer*:ti OR volunteer*:ab OR 
'crossover procedure'/exp OR 'double-blind procedure'/exp OR 'single-blind procedure'/exp 
OR 'randomized controlled trial'/exp OR allocat*:ti OR allocat*:ab AND [embase]/lim 
2 'pycnogenol'/exp OR 'pine bark' AND [embase]/lim 
3 'pine'/exp AND 'bark'/exp AND [embase]/lim 
4 #2 OR #3 
5 #1 AND #4 
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Appendix 4: Assessment of risk of bias in included studies (Higgins 2008)  
 
Domain 1: Sequence generation 
Adequate: investigators described a random component in the sequence generation process 
such as the use of: 
• A random number table; 
• Coin tossing; 
• Throwing dice; 
• Shuffling cards or envelopes. 
 
Inadequate: investigators described a non-random component in the sequence generation 
process such as the use of: 
• Odd or even date of birth; 
• The day or date of admission; 
• The hospital or clinic record number; 
• Preference of the participant; 
• The results of a laboratory test or series of tests. 
 
Unclear: there is insufficient information to permit judgement of the way in which sequence 
generation was performed. 
 
Domain 2: Allocation concealment 
Adequate: neither participants nor investigators enrolling participants could foresee 
assignment due to: 
• Central allocation (e.g. via the telephone or pharmacy-controlled); 
• Sequentially numbered drug containers of a matching appearance; 
• Sequentially numbered, opaque and sealed envelopes. 
 
Inadequate: both participants and investigators enrolling participants could foresee 
upcoming assignment based on, for example: 
• Using an open random allocation schedule; 
• Assigned envelopes were unsealed, non-opaque or not numbered appropriately; 
• Date of birth; 
• Case record number. 
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Unclear: there is insufficient information to permit judgement to the sequence generation 
process. 
 
Domain 3: Blinding 
Adequate: when anyone of the following are applicable: 
• No blinding, but the review judge that the outcome would not be influenced by a 
lack of blinding; 
• Blinding of both the key study personnel and participants are ensured, and it is 
unlikely that blinding could have been broken; 
• Either participants or some key study personnel were not blinded, but the outcome 
measurement was blinded and the non-blinding of others are not likely to introduce 
bias. 
 
Inadequate: when anyone of the following are applicable: 
• No blinding or incomplete blinding; 
• Blinding of key study personnel and participants were attempted, but it is likely that 
the blinding could have been broken; 
• Either key study personnel or participants were not blinded which is likely to 
introduce bias. 
 
Unclear: there is insufficient information to permit judgement, or the study did not address 
this outcome at all. 
 
Domain 4: Incomplete outcome data 
Adequate: when anyone of the following are applicable: 
• No missing outcome data; 
• The reasons for missing outcome data are unlikely to be related to the true 
outcome; 
• Missing outcome data are balanced in numbers across intervention groups; 
• Missing data have been imputed using appropriate methods; 
• For dichotomous data, the proportion of missing outcomes compared with the 
observed event risk is not enough to have a clinically relevant impact on the 
intervention effect estimate; 
• For continuous data, the plausible effect size among missing outcomes is not 
enough to have a clinically relevant impact on the observed effect size. 
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Inadequate: when anyone of the following are applicable: 
• The reason for missing outcome data is likely to be related to true outcome; 
• The application of simple imputation is potentially inappropriate; 
• 'As-treated' analysis done with substantial departure of the intervention received 
from that assigned at randomisation; 
• For dichotomous data, the proportion of missing outcomes compared with the 
observed event risk is enough to introduce clinically relevant bias in the intervention 
effect estimate; 
• For dichotomous outcome data, the plausible effect size among missing outcomes 
is enough to induce clinically relevant bias in the observed effect size. 
 
Unclear: there is insufficient reporting of exclusions to permit judgement, or the study did not 
address this outcome at all. 
 
Domain 5: Selective outcome reporting 
Adequate: when anyone of the following are applicable: 
• The study protocol is available and all of the pre-specified outcomes are addressed 
in the review in the pre-specified way; 
• The study protocol is not available, but it is clear that the published reports include 
all the pre-specified and expected outcomes. 
 
Inadequate: when anyone of the following are applicable: 
• Not all of the pre-specified primary outcomes have been reported; 
• One or more of the primary outcomes is reported using measurements of analysis 
methods that were not pre-specified; 
• One or more reported primary outcomes were not pre-specified; 
• One or more outcomes of interest in the review are reported incompletely so that 
they cannot be entered in a meta-analysis; 
• The study report fails to include results for a key outcome that would be expected to 
have been reported for such a study. 
 
Unclear: there is insufficient information to permit judgement of compliance. 
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Domain 6: Other potential threats to validity 
Adequate: when the study seems to be free of other sources of bias. 
 
Inadequate: when there is the possibility of at least one important risk of bias such as: 
• The quality of the specific study design is in question; 
• The study is stopped early due to some data-dependent process; 
• The study has been claimed to have been fraudulent. 
 
Unclear: when there may be a risk of bias, but there is either: 
• Insufficient information to assess whether an important risk of bias exists; 
• Insufficient rationale or evidence that an identified problem will introduce bias. 
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Appendix 5: Letters to contact authors of relevant included studies  
 
This letters were sent via email on 19 November 2010 and to date we have received three 
replies.  The responses will be incorporated into the Cochrane review. 
 
Belcaro 2006a 
 
Dear Dr G Belcaro  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Clin Appl Thrombosis/Hemostasis 2006;12(3):1-6 with 
the title “Diabetic ulcers: microcirculatory improvement and faster healing with Pycnogenol” 
met our eligibility criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Was the trial conducted in Italy?   
• With regards to the baseline information of the four different groups in Table 
1:  is the age and duration of disease expressed as means, i.e. the 54.3, 11.3, 
55, 11, etc?   
• Can you please describe to us how randomisation was done, in other words 
how were participants divided into the Pycnogenol or placebo group? 
• Was allocation of participants to either of the two groups concealed, in other 
words was something done to protect the investigator from knowing to which 
group the next participant will be allocated?  If yes, how was it done? 
• It is reported in the text that the evaluation of microcirculatory parameters was 
firstly collected at baseline (week 0).  However, in Table 3 it seems like if the 
first data collection was done at week 1 (and thus not at baseline).  Which 
one is correct? 
• With regards to the outcome ‘skin flux at rest’ in Table 3:  the result of the 
control group at week 6 is given as “3.3.8”.  What is the correct value (e.g. 3.8 
or 3.3)? 
• With regards to the outcome ‘change in area of ulceration’:  can you please 
provide the standard deviation of change between baseline and week 6 for 
each of the four groups, or at least for the oral plus local Pycnogenol versus 
control group? 
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• With regards to the outcome ‘change in symptom score’ (Table 2):  can you 
please provide the standard deviation of change between baseline and week 
6 of each of the four groups, or at least for the oral plus local Pycnogenol 
versus control group? 
• With regards to the outcome ‘percentage healing’ (Table 2):  can we please 
get the exact numbers for the 89%, 84%, 85% and 61%, because for 
example, 89% equates to ‘7.12’ people.  Furthermore, can you please explain 
to us what is meant with “percentage healing”?  For example, did all the 
participants had at least one ulcer that healed, or should all ulcers be healed 
per participant before he/she was counted? 
• With regards to the outcome ‘microcirculatory parameters’ (Table 3):  can you 
please provide the standard deviation of change between week 1 (or 
baseline?) and week 6 for each of the three relevant groups (or at least for 
the oral plus local Pycnogenol group and control) for PO2, PCO2 and skin flux 
at rest? 
Thank you very much for your time. 
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Belcaro 2008b 
 
Dear Dr G Belcaro  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Phytotherapy Research 2008;22:518-523 with the title 
“Treatment of osteoarthritis with Pycnogenol.  The SVOS (San Valentino Osteo-arthrosis 
Study).  Evaluation of signs, symptoms, physical performance and vascular aspects.” met 
our eligibility criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• We know from the article that the placebo was identical in terms of appearance to the 
test drug Pycnogenol.  Were there other characteristics that were also matched?   
• Was the treadmill test performed at 3 km/h as in the text or at 8 km/h as in Tables 1 
and 4? 
• On what scale was the WOMAC scores measured (e.g. 5 point Likert scale, visual 
analogue scale etc.)? 
• Do all the reported results include all of the available participants, i.e. 71 in the 
Pycnogenol and 74 in the control group?  If not, can you please tell us how many per 
group? 
• How was the analyses performed, i.e. were the missing data just omitted and were 
the participants analysed according to the group to which they were randomised?   
• With regards to Table 2 (sum of the pain, stiffness, physical function and global 
scores):  can you please provide the standard deviation at baseline and at month 3, 
as well as the standard deviation of change (between baseline and month 3), for 
each of the abovementioned outcomes for both the Pycnogenol and placebo groups? 
• With regards to Table 3 (negative alterations in social functions and sum of emotional 
parameters outcomes):  can you please provide the standard deviation at baseline 
and at month 3, as well as the standard deviation of change (between baseline and 
month 3), for these two outcomes for both the Pycnogenol and placebo groups? 
• With regards to the totals of the placebo group for the outcome ‘sum of emotional 
parameters’ in Table 3:  for inclusion the mean is reported as 28.4 and for month 3 as 
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24.1.  How did you calculate these figures?  If we add up all individual means for 
inclusion and month 3, we get 28.2 and 24.4 respectively.    
• With regards to ‘physical performance’ in Table 4:  can you please provide the 
standard deviation of change between baseline and month 3 for both the Pycnogenol 
and the placebo group? 
• With regards to the use of NSAIDs:  was NSAIDs the only concomitant medication 
that was used?  What is meant with “the use of NSAIDs dropped by 58% during 
treatment with Pycnogenol, whereas under placebo NSAIDs use was reduced by 
only 1%.”?  Can you please provide the actual numbers per group that experienced a 
reduction as well as the total number of participants in each group? 
• With regards to the clinical assessment of ankle and foot edema:  can you please 
give us the number of participants in each group, for baseline and at the end of the 
three months treatment period, that relate to the 76%, 79%, 79% and 1%, as well as 
the total number of participants that were assessed in each group? 
• It is reported that “unwanted effects of treatment were reported by patients in diaries”.  
Can you please explain the results that were reported for this outcome, i.e. 
“evaluation of data demonstrated a decrease of gastrointestinal complications of 63% 
in the Pycnogenol group versus 3% in the placebo group”? 
• In the article published in Redox Report 2008;13(6):271-9 with the title “Variations in 
C-reactive protein, plasma free radicals and fibrinogen values in patients with 
osteoarthritis treated with Pycnogenol” it is reported that the study was sponsored by 
Horphag Research Ltd (UK).  Did they only sponsored the study on the subsample 
(N = 29 + 26 = 55) of participants with CRP-levels  3 mg/l, or did they sponsor the 
whole study (in other words the one reported in Phytotherapy Research 2008;22:518-
523)? 
Thank you very much for your time. 
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Cisár 2008 
 
Dear Dr P Rohdewald  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Phytotherapy Research 2008;22:1087-92 with the title 
“Effect of pine bark extract (Pycnogenol) on symptoms of knee osteoarthritis” met our 
eligibility criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Can you please describe to us how randomisation was done, in other words how 
were participants divided into the Pycnogenol or placebo group? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• We know from the article that the placebo was identical in terms of appearance to the 
test drug Pycnogenol.  Were there other characteristics that also matched? 
• We are not quite sure of the total duration of the trial. It is reported that "patients were 
investigated at the start, at 3 months and 4 weeks after finishing treatment." From 
this quote we understand that the treatment was given for three months (12 weeks) 
after which there was a four week wash-out period before the final follow-up data 
collection was performed (in other words a total study duration of 16 weeks). 
However, the results are reported, amongst other time points, at weeks 12 and 14 as 
well as at week 15 (Figure 5). Can you please point out the total duration of the trial 
as well as the treatment period (e.g. 12 weeks) and the duration of the wash-out 
period (e.g. 2 weeks or 4 weeks)? 
• In the analysis, how was the missing data from the participants lost to follow-up 
handled?  Was it imputed and entered in the analysis or was it omitted (available 
case analysis)? 
• With regards to the results of the two primary outcomes (reduction of symptoms of 
osteoarthritis using WOMAC scores – for pain, stiffness, ability to perform daily 
activity, and total WOMAC score; and reduction of pain using VAS) that are only 
reported in graph form (Figures 1 to 5):  can you please provide either the means and 
standard deviations as well as the standard deviation of change, or the medians and 
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interquartile ranges for baseline and the end of the treatment period separately for 
the Pycnogenol and placebo groups? 
Thank you very much for your time. 
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Duracková 2003 
 
Dear Dr Z Durackova  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Nutrition Research 2003;23:1189-98 with the title “Lipid 
metabolism and erectile function improvement by Pycnogenol, extract from the bark of Pinus 
pinaster in patients suffering from erectile dysfunction – a pilot study” met our eligibility 
criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Was the study conducted in Slovak Republic?   
• Can you please describe to us how randomisation was done, in other words how 
were participants divided into the Pycnogenol or placebo group? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• How did the placebo pill looked with respect to the test drug Pycnogenol, i.e. were 
they identical in some respects? 
• The overall age of the two groups were reported as “average age 46.5 ± 12.5 years”.  
What kind of measure of variation is the 12.5, i.e. standard deviation (SD), standard 
error of the mean (SEM) etc.?  Is it possible to give us the mean age ± SD of each 
group separately? 
• The ‘average ED score’ (measured by IIEF-5) is reported as 12.6 ± 1.1.  What 
measure of variation is the ‘1.1’, i.e. SD or SEM?  Can you please provide the mean 
baseline scores and the SD or SEM for the Pycnogenol and placebo group 
separately? 
• Can you perhaps provide baseline characteristics of the two groups (separately) e.g. 
age, mean duration of disorder, weight or body mass index, smoking habits? 
• It is reported that moderate ED = 11 to 15 points and severe ED = “less than 10 
points”.  In what category does a score of 10 fit into? 
• With regards to the outcome ‘change in IIEF-5 scores’:  can you please provide the 
mean of the placebo group at the end of the three months treatment period as well as 
the SEM of change for the period between baseline and month 3 for both the 
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Pycnogenol and placebo groups? Otherwise the exact p-value of the change 
between the two groups will also help.   
• With regards to the outcome ‘change in antioxidant activity’ (measured by FRAP):  
can you please provide the mean difference for both the Pycnogenol and the placebo 
group, as well as the SEM of change between baseline and month 3 for the two 
groups? 
Thank you very much for your time. 
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Farid 2007 
 
Dear Dr RR Watson  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Nutrition Research 2007;27:692-97 with the title 
“Pycnogenol supplementation reduces pain and stiffness and improves physical function in 
adults with knee osteoarthritis” met our eligibility criteria and is therefore one of our included 
studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Can you please describe to us how randomisation was done, in other words how 
were participants allocated to the Pycnogenol or placebo group? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• We know from the article that the placebo was identical in terms of appearance to the 
test drug Pycnogenol.  Were there other characteristics that also matched? 
• For the outcomes ‘change in pain, ‘change in stiffness’, ‘change in physical function’ 
and ‘change in composite WOMAC score’:  can you please provide the standard 
deviation of change between baseline and day 90 for both the Pycnogenol and the 
placebo groups?   
• For the outcome ‘frequency and dose of additional medication usage (NSAIDs and 
COX-2)’:  can you please provide the actual numbers of Fig.3A and Fig.3B of 
baseline and month 3, as well as the standard deviation of change between baseline 
and month 3 for both the Pycnogenol and the placebo groups? 
• There were two missing participants at the end of the treatment period. Can you 
please describe how you have dealt with it in the intention-to-treat analysis?   
Thank you very much for your time. 
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Hosseini 2001a 
 
Dear Dr RR Watson  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in the Journal of Medicinal Food 2001;4(4): 201-209 with 
the title “Pycnogenol in the management of asthma” met our eligibility criteria and is 
therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Can you please describe to us how randomisation was done, in other words how 
were participants divided into the Pycnogenol or placebo group? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• How did the placebo pill looked with respect to the test drug Pycnogenol, i.e. were 
they identical in some respects? 
• Did you perform any tests for carry-over effect?  If yes, how was it performed? 
• Is it possible to please provide the reason why each of the seven participants 
withdrew from the study? 
• With regards to results for the outcome ‘asthma symptom scores’ (Figure 3):  can you 
please provide the mean and standard error of the differences between Pycnogenol 
and placebo measurements?  If it is possible, can you please also tell us how many 
people in each group showed a decrease of symptoms at the end of the treatment 
period, compared to baseline?  We will then also need the number of participants 
that were assessed in each of the Pycnogenol and placebo periods. 
• With regards to the outcomes ‘FEV1’ and ‘FEV1/FVC’:  can you please provide the 
standard deviation of change for each of these two outcomes, for the Pycnogenol 
and placebo periods?  
Thank you very much for your time. 
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Hosseini 2001b 
 
Dear Dr RR Watson  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  The article published in Nutrition Research 2001;21:1251-60 with the title “A 
randomized, double-blind, placebo-controlled, prospective, 16 week crossover study to 
determine the role of Pycnogenol in modifying blood pressure in mildly hypertensive 
patients” met our eligibility criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Was the study conducted in the USA? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• How did the placebo pill looked with respect to the test drug Pycnogenol, i.e. were 
they identical in some respects? 
• Did you perform any tests for carry-over effect?  If yes, how was it performed? 
• With regards to the outcome ‘systolic and diastolic blood pressure’:  can you please 
provide the mean and standard error of the differences between the Pycnogenol and 
placebo measurements? 
• Was ‘change in use of concomitant medication’ an outcome that was measured?  Or 
was it only monitored to make sure that the usage stayed the same throughout the 
treatment period? 
• There are no results reported for the blood tests for safety which was specified in the 
Methods section of the article.  What parameters were tested with these blood 
chemical tests and what were the results?  It is reported that blood collection 
occurred at the end of week 7, week 15 and 16.  Was it collected at the end of week 
8 as well?   
Thank you very much for your time. 
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Lau 2004 
 
Dear Dr BHS Lau 
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in the Journal of Asthma 2004;41(8):825-32 with the title 
“Pycnogenol as an adjunct in the management of childhood asthma” met our eligibility 
criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Can you please describe to us how randomisation was done, in other words how 
were participants divided into the Pycnogenol or placebo group? 
• Can you please tell us more about the coding of the bottles of placebo and 
Pycnogenol:  were there two different codes - one for placebo and one for 
Pycnogenol - or did every one of the sixty bottles had a different code?  What was 
the code like, e.g. how many numbers per code?   
• What happened during the one week run-in period before the start of the study? 
• Were only rescue inhaler (albuterol) and oral medication (Accolate) permitted during 
the trial as concomitant medication? 
• Did all 60 participants finished the three months intervention period and was data of 
all outcomes for every participant collected?  If not, how was the missing data 
accounted for in the analyses? 
• With regards to the outcome ‘change in peak expiratory flow rate (PEF)’:  can you 
please provide the mean ± standard error of the mean (SEM) for the Pycnogenol and 
the placebo group at the three months time point; as well as the standard deviation of 
change (between baseline and end of month 3) for both the Pycnogenol and the 
placebo group?  In addition we would like to know why, in Figure 2, is the y-axis 
labeled “median symptom scores” but in the text beneath the figure it is reported as 
“means ± SEM”? 
• With regards to the outcome ‘change in symptom scores’:  can you please provide 
the mean ± SEM for the placebo group for both the baseline and the three months 
time point; as well as the standard deviation of change (between baseline and end of 
month 3) for both the Pycnogenol and the placebo group? 
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• With regards to the outcome ‘change in use of rescue inhaler’:  can you please 
provide us, for the period between baseline and month 3, with the standard deviation 
of change for both the Pycnogenol and placebo groups? 
• The following quote comes from the article’s Methods section:  "Bottles of 
Pycnogenol or placebo (provided by Horphag Research, Geneva, Switzerland) were 
identified by preassigned codes..."  However, the following quote comes from the 
Acknowledgement section:  “This study was supported by the Chan Shun 
International Foundation, San Francisco, CA, and Horphag Research, Geneva, 
Switzerland. Neither of the sponsors is the manufacturer of the Pycnogenol capsules 
used in this study."  Now we are unsure whether Horphag Research provided the 
Pycnogenol and placebo capsules or not? 
Thank you very much for your time. 
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Liu 2004a 
 
Dear Dr P Rohdewald  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Life Sciences 2004;75:2505-13 with the title 
“Antidiabetic effect of Pycnogenol French maritime pine bark extract in patients with diabetes 
type II” met our eligibility criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Can you please describe to us how randomisation was done, in other words how 
were participants divided into the Pycnogenol or placebo group? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• How did the placebo pill looked with respect to the test drug Pycnogenol, i.e. were 
they identical in some respects? 
• Was the Pycnogenol and placebo consumed orally, and how frequent was the 
Pycnogenol and placebo consumed? 
• With regards to the outcome ‘change in nitrogen monoxide levels’:  it is reported on 
page 2509 that “concentrations of nitric monoxide in plasma increased over the 
treatment period in both groups, with a tendency to higher values in the Pycnogenol 
group...”.  Can you please provide the mean ± standard deviation for baseline and 
week 12 for the Pycnogenol and placebo groups, as well as the standard deviation of 
change for the two groups separately? 
• Was the study funded?  If yes, can you please provide us with the name(s) of the 
company or institution? 
Thank you very much for your time. 
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Liu 2001c 
 
Dear Dr P Rohdewald  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  The article published in Life Sciences 2004;74:855-62 with the title “Pycnogenol, 
French maritime pine bark extract, improves endothelial function of hypertensive patients” 
met our eligibility criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Can you please describe to us how randomisation was done, in other words how 
were participants divided into the Pycnogenol or placebo group? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• How did the placebo pill looked with respect to the test drug Pycnogenol, i.e. were 
they identical in some respects? 
• Was the Pycnogenol and placebo consumed orally, and how frequent was the 
Pycnogenol and placebo consumed? 
• With regards to the outcome ‘change in nitrogen monoxide levels’:  it is reported on 
page 860 that “concentrations of nitric monoxide in plasma increased over the 
treatment period in both groups...differences in comparison to placebo failed to reach 
statistical significance.”.  Can you please provide the mean ± standard deviation for 
baseline and week 12 for the Pycnogenol and placebo groups, as well as the 
standard deviation of change for the two groups separately? 
• Was the study funded?  If yes, can you please tell us who the funder(s) were? 
Thank you very much for your time. 
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Petrassi 2000 
 
Dear Dr C Petrassi  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Phytomedicine 2000;7(5):383-88 with the title 
“Pycnogenol in chronic venous insufficiency” met our eligibility criteria and is therefore one of 
our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions:   
• Was the study conducted in Italy?   
• The mean age together with a unit of variation is given for the Pycnogenol and 
placebo groups:  “47.7 ± 3.65 years” and “36.7 ± 3.66 years” respectively.  What 
measure of variation is used (e.g. standard deviation)? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• Were the values in Table 1 reported as mean ± standard deviation as mean ± 
standard error? 
• For the outcome ‘change in heaviness score’:  can you please provide the standard 
deviation of change between baseline and day 60 for both the Pycnogenol and 
placebo groups?  
• For the outcome ‘change in swelling score’:  can you please provide the standard 
deviation of change between baseline and day 60 for the Pycnogenol and placebo 
groups? 
• For the outcome ‘change in pain score’:  can you please provide the mean and 
standard deviation of baseline and Day 60 for both groups, as well as the standard 
deviation of change between baseline and day 60 for both the placebo and 
Pycnogenol groups? 
• Results for the outcomes ‘change in night cramps’ and ‘change in paraesthesiae’ are 
not reported.  Can you please provide the mean and standard deviation for baseline 
and day 60 for both groups, as well as the standard deviation of change between 
baseline and day 60 for both the placebo and Pycnogenol groups? 
• For the outcomes ‘change in heaviness’, ‘change in swelling’, ‘change in night 
cramps’, ‘change in pain’, and ‘change in parasthesiae’:  can you perhaps also tell us 
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how many people per group experienced disappearance of each symptom at the end 
of the treatment period compared to baseline; as well as the total number of 
participants in each group for each symptom? 
• Can you perhaps provide the data for only the randomised phase of the trial (n = 20) 
for the outcomes ‘ambulatory venous pressure’ and ‘physician’s judgement of 
efficacy and safety of treatment’?  Since we only include randomised controlled trials 
in our systematic review we unfortunately cannot use the results if it is pooled with 
the non-randomised arm of the study. 
• Was the study funded?  If yes, can you please tell us who the funder(s) were? 
Thank you very much for your time. 
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Steigerwalt 2009 
 
Dear Dr F Schönlau  
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  The article published in Journal of Ocular Pharmacology and Therapeutics 
2009;25(6):537-540 with the title “Pycnogenol improves microcirculation, retinal edema, and 
visual acuity in early diabetic retinopathy” met our eligibility criteria and is therefore one of 
our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions:   
• Was the study conducted in Italy?   
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• How did the placebo pill looked with respect to the test drug Pycnogenol, i.e. were 
they identical in some respects? 
• Is the baseline data in Table 1 reported as the mean ± standard deviation?   
• Can you please provide the mean ± standard deviation as well as the standard 
deviation of change (mild and moderate retinal edema cases combined) between 
baseline and month 2 for both the Pycnogenol and the placebo groups for the 
following outcomes:  retinal thickness, retinal edema score, diastolic flow relative to 
max systolic flow, retinal blood flow, and visual acuity (Snellen chart)?   
• With regard to the outcome ‘diastolic flow relative to max systolic flow’:  can you 
please give us the median of change and the range of change between baseline and 
month 2 for both the Pycnogenol and the placebo groups? 
• On page 539 (Results section) it is reported that "eighteen out of a total of 23 patients 
taking Pycnogenol reported subjectively perceived visual improvement."  But on page 
540 (Discussion section) it is reported that "the degree of visual improvement, 
however, was impressive as patient's themselves, 18 out of a total of 24 taking 
Pycnogenol, perceived this effect."  Should it be 23 of 24?  If it should be 23, why?  It 
is reported that no participants were lost to follow-up.  Furthermore, nothing about the 
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placebo group is reported.  Can you please provide the results for the placebo 
group? 
• Nothing about the funding source was reported.  Was the study funded?  If yes, by 
whom? 
Thank you very much for you time. 
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Trebatická 2006 
 
Dear Dr J Trebatická 
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Eur Child Adolesc Psychiatry 2006:15:329-335 with the 
title “Treatment of ADHD with French maritime pine bark extract, Pycnogenol” met our 
eligibility criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• How was “double-blinding” achieved?   
• With regards to the baseline characteristics that are reported in Table 1: are the 
“average” weight reported together with its standard deviation, or what measure of 
variation is reported?  Is the BMI reported as a mean ± standard deviation?   
• With regards to the outcome ‘change in inattention’:  can you please provide the 
mean difference and standard deviation of change between the Pycnogenol and 
placebo groups for the period between baseline and month 1 for the CAP, CTRS and 
CPRS tests? Otherwise the final means of each group at the end of month 1 and the 
exact p-value comparing the final values of the two groups are also fine. 
• With regards to the outcome ‘change in hyperactivity’:  can you please provide the 
mean difference and standard deviation of change between the Pycnogenol and 
placebo groups for the period between baseline and month one for the CAP, CTRS 
and CPRS tests? Otherwise the final means of each group at the end of month 1 and 
the exact p-value comparing the final values of the two groups are also fine. 
• With regards to the outcome ‘visual-motoric coordination and concentration’:  can you 
please provide the mean difference and standard deviation of change between the 
Pycnogenol and placebo groups for the period between baseline and month 1? 
Otherwise the final means of each group at the end of month 1 and the exact p-value 
comparing the final values of the two groups are also fine. 
• Can you please explain what you mean with an “intention-to-treat analysis”?  Were 
values for the four participants that dropped out of the study included in the analysis? 
Thank you very much for your time. 
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Dear Dr Z uraková 
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Nutritional Neuroscience 2007;10(3/4):151-157 with the 
title “Urinary catecholamines in children with attention deficit hyperactivity disorder (ADHD): 
Modulation by a polyphenolic extract from pine bark (Pycnogenol)” met our eligibility criteria 
and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• At what time point(s) were GSSG and GSH tested?  It is reported that “whole blood 
was used for determination of total and oxidized glutathione”.  What is the name of 
the laboratory process used for the analysis of GSSG and how was reduced 
glutathione (GSH) determined? 
• With regards to the outcome ‘GSH/GSSG’:  can you please provide the mean at 
baseline and mean at month 1 for the Pycnogenol and placebo groups, as well as the 
standard deviation of change from baseline to month 1 for both the placebo and 
Pycnogenol groups?  Can you please also explain why you used n = 28 
(Pycnogenol) and n = 13 (placebo) instead of n = 44 and n = 17 respectively? 
Thank you very much for your time. 
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Zibadi 2008 
 
Dear Dr RR Watson 
 
We are conducting a systematic review with the title “Pycnogenol for the treatment of chronic 
disorders”.  Your article published in Nutrition Research 2008;28:315-20 with the title 
“Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol 
supplementation” met our eligibility criteria and is therefore one of our included studies.   
 
In order to get more insight into the study, we will appreciate it if you can help us by 
answering the following questions: 
• Was the study conducted in the USA? 
• Can you please describe to us how randomisation was done, in other words how 
were participants divided into the Pycnogenol or placebo group? 
• Was allocation of participants to either of the two groups concealed, in other words 
was something done to protect the investigator from knowing to which group the next 
participant will be allocated?  If yes, how was it done? 
• In terms of what characteristics was the placebo “matched” with the test drug 
Pycnogenol? 
• A total of three participants were lost to follow-up, 2 from the placebo and 1 from the 
Pycnogenol group.  How were data for these participants handled, e.g. the data you 
had for them, were it part of the analyses and the missing data just omitted, or were 
the missing data imputed? If imputed, how? 
• In Table 1 where the percentage participants in each group that used different types 
of antidiabetic medications were reported:  can you please give us the numbers that 
relates to the percentages?  Because if we take 6% × 24 participants we get ‘1.44’ 
participants.  Also, if one sums the percentages of the Pycnogenol group you get 
100%, but for the placebo group it only adds up to 95%.  Were there some 
participants who used other kinds of oral antidiabetic medication?   
• Was ‘change in use of concomitant antidiabetic medication’ an outcome, or was it 
only monitored to make sure that the usage stayed the same throughout the 
treatment period? 
• With regards to the outcome ‘change in glucose levels’:  can you please provide the 
standard error of the mean (SEM) of change between baseline and week 12 for the 
placebo group? 
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• With regards to the outcome ‘change in Hb1Ac levels’:  can you please provide the 
SEM of change between baseline and week 12 for both the Pycnogenol and placebo 
groups? 
• With regards to the outcome ‘change in urinary albumin levels’’:  can you please 
provide the SEM of change between baseline and week 12 for the placebo group? 
• With regards to the outcome ‘compliance with the test drug or placebo’:  can you 
please provide the number of participants that relates to the following percentages:  
94% of the Pycnogenol group and 96% of the placebo group?  Does this outcome 
include those participants that were lost to follow-up?   
• With regards to the measurement ‘heart rate’:  there are no results reported.  Was 
heart rate measured as a safety measure?  Is it possible to give us results for it? 
Thank you very much for your time. 
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CLOSING REMARKS 
 
Complementary medicine refers to any substance which originates from a plant, mineral or 
animal which is used for complementing the healing power of the human body.(14)  Nutritional 
supplements, a type of complementary medicine, is defined as a product intended to 
increase the total dietary intake, containing at least one of the following:  a vitamin, mineral, 
herb or amino acid.(15)  Seventy to eighty percent of people in developing countries have 
used some form of complementary medicine.(16)  In recent years the South African market 
has been flooded by complementary medicines.  This extremely profitable market are today 
largely unregulated.(17)  This raises concern about the efficacy and safety of these products. 
 
Nutritional supplements, amongst other complementary medicines, are advertised widely in 
South Africa, especially in the printed media.  Often these advertisements contain a variety 
of claims, especially health claims.  People not familiar with the field of science can easily be 
influenced to buy nutritional supplements because of advertisements containing promising 
claims.  Claims should be supported by good research evidence.   
 
Procydin, with proanthocyanidin as the main ingredient, is a popular nutritional supplement 
in South Africa.  Pamphlets in pharmacies and advertisements in newspapers and 
magazines promote Procydin to benefit people who suffer from “diabetes, arthritis, 
cardiovascular diseases, high cholesterol, high blood pressure and arteriosclerosis”. 
Because many family members and friends use this antioxidant supplement it was decided 
to investigate what the evidence behind this product is.   
 
The researchers are not aware of any clinical trials with Procydin as the intervention, and 
therefore the title of the initial protocol was ‘Proanthocyanidin supplements for the treatment 
of chronic disorders’.  However, when conducting the search it was found that the majority of 
studies involve Pycnogenol, a standardised formulation of French maritime pine bark extract.  
Secondly it was realised that there is a lack of specificity of proanthocyanidin-containing 
products.  Apart from proanthocyanidin, the majority of these supplements also contain a 
variety of other compounds and the various supplements vary widely in content.  
Furthermore the source of proanthocyanidin varies (pine bark, grape seed, cranberries etc.) 
as do the additional ingredients across the various supplements.  Since Pycnogenol is the 
most researched proanthocyanidin-containing product and the manufacturer believes that 
their product is a “well-researched, evidence-based product” it was decided that a systematic 
review focusing on Pycnogenol would be more useful.  As a consequence of this change in 
xxi 
 
title, we have revised the following sections of the initial protocol: 'Description of the 
intervention', 'Objectives' and 'Criteria for considering studies for this review'.  
 
The conclusion of this systematic review is that current evidence is insufficient to support 
Pycnogenol use for the treatment of any chronic disorder.  The impact of this finding is far 
reaching as this conclusion is not only applicable to Pycnogenol but also to all the other 
proanthocyanidin-containing supplements available worldwide, including Procydin, whose 
health claims are based on the clinical evidence of Pycnogenol.  Furthermore, this example 
can strengthen the rationale for the need of an effective international regulating authority.  
Well-designed, adequately powered randomised controlled trials of Pycnogenol are needed 
to accurately assess the efficacy and safety of this product for the treatment of chronic 
disorders. 
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